US.MRK · Merck & Co.

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.8,
      "details": {
        "atrPct": 2.6589242891401166,
        "turnoverUsdM": 1639.3833749999997,
        "liquidityPoints": 0.8,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.MRK",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 138.1886,
      "strength_details": {
        "ma_score": 2,
        "atr_score": 2,
        "rsi_score": 1,
        "macd_score": 2.5,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.2,
      "stop_loss_percent": 5.3,
      "take_profit_price": 155.4124,
      "target_multiplier": 1.9,
      "technical_strength": 1.93,
      "take_profit_percent": 6.5
    },
    "positionPoints": 1.8,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2222988120699874,
    "stopLossPercent": 5.317848578280233,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 62.1,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 53.1,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 9
  },
  "market": {
    "ma20": 145.7415,
    "ma50": 145.1234,
    "close": 145.95,
    "prevClose": 145.19,
    "avgVolume20": 9199905,
    "volumeRatio": 1.22,
    "changePercent": 0.52
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 9,
    "details": {
      "ret_5d": 0.0024037773074327973,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 9,
      "vcp_bonus": 0,
      "vol_ratio": 1.1016288807715373,
      "ret_points": 4,
      "vol_points": 2,
      "range_ratio": 0.5672816560934039,
      "volat_points": 0,
      "day_range_pct": 0.015005138746145926,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 62.1,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.2,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 44,
        "contribution": 2.2
      },
      {
        "raw": 9.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 46,
        "contribution": 9.2
      },
      {
        "raw": 8.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 57.33,
        "contribution": 8.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 70,
        "contribution": 7
      },
      {
        "raw": 20.1,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 67,
        "contribution": 20.1
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "避免",
    "result": 53.1,
    "details": [
      "基本面分析總分: 2.2/5分",
      "資金流分析總分: 9.2/20分",
      "市場環境分析總分: 8.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7/10分",
      "技術信號分析總分: 20.1/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.2,
      "資金流": 9.2,
      "市場環境": 8.6,
      "情緒分析": 4,
      "技術信號": 20.1,
      "風險管理": 7
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 1639.3833749999997,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 1.6,
          "obvPoints": 4,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.MRK",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 16.46
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 742.51900315,
                "ma50": 726.7734006600002,
                "name": "QQQ",
                "close": 709.79999,
                "points": 0.4
              },
              "spy": {
                "ma20": 771.1839966499999,
                "ma50": 768.5017965800001,
                "name": "SPY",
                "close": 763.25,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.6589242891401166,
          "atrPoints": 3,
          "cciPoints": 2.4,
          "vixPoints": 2.4,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 0.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142921419,
                "url": "https://finnhub.io/api/news?id=8f0d78d8d5689e7fbdbb1090314c843e5e4db03b72a98e036f4960d0e46006f5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (NYSE:MRK) plans to unveil first-time pivotal Phase 3 oncology data at ESMO 2026, including melanoma and endometrial cancer trials. The company will share late-breaking results from multiple oncology pipeline programs that extend beyond its currently marketed cancer therapies. Merck is pairing the scientific presentations with an Oncology Investor Event focused on its next wave of cancer drug candidates and plans. The first-time pivotal Phase 3 oncology results at ESMO 2026 deserve to...",
                "category": "company",
                "datetime": 1792091518,
                "headline": "What Could Merck (MRK) Reveal At ESMO 2026 About Its Oncology Pipeline?"
              },
              {
                "id": 142920416,
                "url": "https://finnhub.io/api/news?id=e1edfeb2d3d1b855f41641b69760edc6c7630a45db8b820a950c2052acbfe992",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Amgen and Merck both yield around 2.3% and have surged this year, but one of them is paying its dividend out of thin air while the other has a cash cushion that changes the entire income calculus.",
                "category": "company",
                "datetime": 1792082725,
                "headline": "AMGN vs. MRK: Which Pharma Giant’s Dividend Actually Has Room to Grow"
              },
              {
                "id": 142919309,
                "url": "https://finnhub.io/api/news?id=dd209d7cc5c57c1fdbe0bfcb962ee233f615afcc0e3601c6a02d0b34c87dbc45",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Baillie Gifford & Co, an independent investment management firm, released its third-quarter 2026 investor letter for “International Concentrated Growth Strategy”. A copy of the letter can be downloaded here. The strategy outperformed its benchmark in the third quarter of 2026, as strong company-specific developments in biotechnology and digital platforms helped offset weakness in parts of […]",
                "category": "company",
                "datetime": 1792078066,
                "headline": "Merck & Co., Inc. (MRK) Reports Promising Skin Cancer Trial Results for Keytruda and Personalized mRNA Vaccine"
              },
              {
                "id": 142916390,
                "url": "https://finnhub.io/api/news?id=250f1b4bc486c7a38cc4ac6f6504cad4456b03bbbedb9cebdcd617a4bbd4c39b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
                "category": "company",
                "datetime": 1792065608,
                "headline": "Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock"
              },
              {
                "id": 142905234,
                "url": "https://finnhub.io/api/news?id=7d8c4f5e9906d8daf56691e3b6df0f1fb2257add117c1a699f2860e2809ea2c2",
                "image": "https://www.chartmill.com/images/uploads/thumbnail_article_luc_kroeze_c1f44c837d.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Merck & Co. (MRK) quality investing analysis: strong ROIC, cash conversion, low debt/FCF, but revenue growth misses Caviar Cruise screen.",
                "category": "company",
                "datetime": 1792053086,
                "headline": "Merck & Co. (NYSE:MRK): A Quality Investing Case With Strong ROIC but Revenue Growth Concerns"
              },
              {
                "id": 142854484,
                "url": "https://finnhub.io/api/news?id=46d3388160bf922ff28dc0ffdfea7cf4af9cc49f84ba05a23f08b315ba443b2b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) concluded the recent trading session at $141.98, signifying a -2.39% move from its prior day's close.",
                "category": "company",
                "datetime": 1791924603,
                "headline": "Merck (MRK) Dips More Than Broader Market: What You Should Know"
              },
              {
                "id": 142852471,
                "url": "https://finnhub.io/api/news?id=69df73ce666e8a3721fe511dbc01de11fb7e86bdd2db9119f0a1969d817e5ffd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck & Co., Inc. (NYSE:MRK) closed at $145.45 on October 12. The stock has returned 21% during the last six months, compared to a 21.25% return for the Insider Monkey Billionaire Index and 14% for State Street SPDR S&P 500 ETF Trust. A company that keeps three-quarters of its revenue as gross profit does not […]",
                "category": "company",
                "datetime": 1791913155,
                "headline": "Merck (MRK) Reports a Negative Operating Margin and Pays Out 266% of Earnings. What Explains Both?"
              },
              {
                "id": 142823704,
                "url": "https://finnhub.io/api/news?id=984bfb1d59f4f7391eb1a78f22a944db80d76ae1b13befab7b635efbc22b03e3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (NYSE:MRK) reported one year pivotal Phase 2b/3 data for remigromig in diabetic macular edema, showing non inferior efficacy to a leading anti VEGF therapy. The company described remigromig's safety profile in the trial as manageable, supporting its potential use in diabetic macular edema patients. Management indicated that the late stage data on remigromig supports progress toward potential regulatory discussions for this ophthalmology candidate. The new remigromig trial results...",
                "category": "company",
                "datetime": 1791828462,
                "headline": "Could Merck (MRK) Have A New DME Option After Its Late Stage Trial Data?"
              }
            ],
            "raw_source": [
              {
                "id": 142958499,
                "url": "https://finnhub.io/api/news?id=b1420296c8a567dcd40c8432fd47e28578939718a62fe248eb6f1b4c039ba42a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna was recently added to the Nasdaq-100 Index after positive Phase 3 data for its personalized cancer vaccine with Merck highlighted a pivot toward oncology beyond COVID-focused products. The late-stage success of intismeran positions Moderna's mRNA platform as a potential multi-product franchise across cancer and other conditions rather than a single-therapy story. Next, the focus turns to how this cancer vaccine progress could reshape Moderna's broader investment narrative around...",
                "category": "company",
                "datetime": 1792210915,
                "headline": "Phase 3 Cancer Vaccine Success Could Change The Case For Moderna Stock"
              },
              {
                "id": 142957851,
                "url": "https://finnhub.io/api/news?id=7fbbc87921f5eb6aebe1a84de39e7ad8c2e918ec67c718d7d159b99c51415cdb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "An investor who put $10,000 into Eli Lilly (LLY) stock on October 14, 2025 held about $15,500 by October 15, 2026. Placing that same sum in the S&P 500 over the identical period would have yielded about $11,790. By mid-2026, two drugs, Zepbound and Mounjaro, accounted for most of the company's sales. How early did those two drugs show up in what Lilly said and filed.",
                "category": "company",
                "datetime": 1792205822,
                "headline": "What Was Eli Lilly Telling You Before Its Stock Ran?"
              },
              {
                "id": 142955409,
                "url": "https://finnhub.io/api/news?id=ddb56e3c9661675f49062aebfa86d5d29be9a5e9841df1481875ad51a4717ce5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Amgen (AMGN) raised its revenue forecast for fiscal 2026 on August 4. Since the market close before that release, the stock has gained 15.2%, outpacing the 1.9% return of the S&P 500. A higher forecast or a climbing share price means little in isolation. When the corporate numbers and the technical chart align, however, the combination warrants closer scrutiny. So how far did management raise its forecast, and why.",
                "category": "company",
                "datetime": 1792198389,
                "headline": "When Amgen's Forecast And Chart Say The Same Thing, Pay Attention"
              },
              {
                "id": 142954216,
                "url": "https://finnhub.io/api/news?id=4ceb14cf168e6a03b7c306392042043ca662a3e864ad75e2c2967d3eb042758f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Gilead Sciences (GILD) built its foundation on HIV treatment. Biktarvy alone accounted for $14.3 billion of the company's $29.4 billion in fiscal 2025 revenue. Yet another segment of the HIV business is growing at a much faster pace, and it targets people who do not currently carry the virus. Gilead expects a regulatory decision regarding a new option in this category in early 2027. So what is that business, and how much is it selling today.",
                "category": "company",
                "datetime": 1792197478,
                "headline": "Gilead’s HIV Prevention Business Just Topped $1 Billion A Quarter. What Comes Next?"
              },
              {
                "id": 142953213,
                "url": "https://finnhub.io/api/news?id=e0d5644bdb1a894b876cd8a527913e2c730f1125e7d0685ae819033f70376096",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Investors holding shares of Amgen (AMGN), the $234 billion maker of drugs such as Repatha and Prolia, likely pair that position with broad exposure to the S&P 500. As the broader market rises and falls each day, the pharmaceutical stock's individual performance blends with the rest of that capital. So when the market drops, does Amgen make your losses bigger.",
                "category": "company",
                "datetime": 1792196033,
                "headline": "Is Amgen Stock Increasing Your Market Risk?"
              },
              {
                "id": 142951534,
                "url": "https://finnhub.io/api/news?id=a6ec6823402e68ad6ddd5bb35f18a9ec64b21a46ee6a9622a167015e67770089",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.",
                "category": "company",
                "datetime": 1792183740,
                "headline": "Moderna Stock Slumps, but It’s Too Early to Panic"
              },
              {
                "id": 142950824,
                "url": "https://finnhub.io/api/news?id=74963cb0e70ab8059f861c09846021096b759eb7a9602add0dbe79b1eea9591b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.",
                "category": "company",
                "datetime": 1792179360,
                "headline": "Moderna and Novavax Stocks Slump as Biotech’s Rally Takes a Breather"
              },
              {
                "id": 142949141,
                "url": "https://finnhub.io/api/news?id=7f878e1d7b8e6ca6594ebcc4d0bd6c82c52bece760c60ab0ea552e559d275df8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Bristol Myers Squibb has raised its dividend for 17 straight years, but a looming patent cliff and $43 billion in debt put the pace of future increases on a collision course with the drugs Wall Street is betting everything on.",
                "category": "company",
                "datetime": 1792172719,
                "headline": "Bristol Myers Squibb’s 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know"
              },
              {
                "id": 142949117,
                "url": "https://finnhub.io/api/news?id=7c834a7f66d845c3fd5471a2eb3bd0c515377886450be67a9025294c95c874a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "AbbVie Inc. (NYSE:ABBV) and Merck & Co., Inc. (NYSE:MRK) have something important in common that is important for investors, which is that both must demonstrate that newer medicines can sustain earnings as their established blockbusters face competition. However, the companies are at different stages of that transition, creating an interesting valuation dilemma. According to Yahoo […]",
                "category": "company",
                "datetime": 1792172175,
                "headline": "AbbVie vs. Merck: Which Pharma Stock Offers Better Value?"
              },
              {
                "id": 142949139,
                "url": "https://finnhub.io/api/news?id=0d7532401f6e6aedd5ff0e5afa4232a56abbd03de1c64f7c8773cb1eb0a30424",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck stock has been in an uptrend. A bullish options strategy aims to profit if the drugmaker's stock keeps rising.",
                "category": "company",
                "datetime": 1792168861,
                "headline": "Merck Stock: Watch This Price, Prepare To Profit From This Trade"
              },
              {
                "id": 142949140,
                "url": "https://finnhub.io/api/news?id=edc23a246eb38307c4b5bf81a56d76dec425080eb91630c8eaf53c0e834a2482",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck & Co., Inc. (NYSE:MRK) has surged over 38% in 2026 so far, outperforming the broader market. Merck is no longer being valued like a pharmaceutical company whose biggest challenge is looming patent pressure. Yahoo Finance puts the stock at 15.29 times forward earnings, compared with 8.56 times at the end of September 2025. The […]",
                "category": "company",
                "datetime": 1792166402,
                "headline": "Merck’s Rally Reflects Renewed Confidence, but Has the Market Priced in Too Much?"
              },
              {
                "id": 142948002,
                "url": "https://finnhub.io/api/news?id=e586d9fa75f4bb019a822871751834ee14425871a48920ab8652e36bf3d86a7a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna sank as Wall Street grew more cautious on the company's valuation after a massive rally this year.",
                "category": "company",
                "datetime": 1792164153,
                "headline": "Moderna stock sinks as Wall Street turns cautious following blistering rally"
              },
              {
                "id": 142948003,
                "url": "https://finnhub.io/api/news?id=9dbc95242c8d52265d5c0557a75bf5612f2300b046560659575730db61480277",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna stock is shedding 10% after a blistering cancer vaccine run, and the question now is whether profit takers know something the bulls don't ahead of a critical trial readout later this month.",
                "category": "company",
                "datetime": 1792162163,
                "headline": "Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put"
              },
              {
                "id": 142948004,
                "url": "https://finnhub.io/api/news?id=3baf1ee24e890652fecbebc36de430f14066942b4fdd1616633ea9c823267896",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna (MRNA) stock has gained 282.6% over the past three months, outpacing a 4.1% return for the S&P 500. The shares reached their highest close in a year on October 15, 2026, ending the session at $236.50. Investors paying that premium are betting the drugmaker is ready to grow again. To meet those expectations, its sales, nearly all from COVID vaccines, have to stop shrinking, while its newer vaccines and cancer drugs have to start selling. Has the business caught up with Moderna's share pri",
                "category": "company",
                "datetime": 1792161868,
                "headline": "What Is The Case For Waiting On Moderna Stock?"
              },
              {
                "id": 142945597,
                "url": "https://finnhub.io/api/news?id=417b8239ccec864a5ac691231b8f2019ed48186bfc07b59a2d383eda26bb1236",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "When tech stocks crack, most investors discover too late that their portfolios were far more concentrated than they realized. Jim Cramer and others are pointing to a handful of quiet winners that keep paying dividends no matter what chip stocks do.",
                "category": "company",
                "datetime": 1792156812,
                "headline": "The Stocks That Will Get Investors Home Safe When Tech Cracks"
              },
              {
                "id": 142947639,
                "url": "https://finnhub.io/api/news?id=2849d0ac5038a97fc9e2dc41b2da58d5dbeae2e3c1c739eaab8a464d56a914f3",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/16/Charts-Of-Financial-Instruments-With-Var.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Nine of 11 sectors are higher in Friday’s regular session, with cyclical sectors holding the top three positions. The leaders are separated rather than clustered, with no single gap clearly standing apart from the other breaks across the table.",
                "category": "company",
                "datetime": 1792148420,
                "headline": "9 Of 11 Sectors Rise In Friday Trading As Cyclicals Lead"
              },
              {
                "id": 142921686,
                "url": "https://finnhub.io/api/news?id=1acfb8f181fa92d06970adec64ca819ba0b9d8103d77fe0fefad6234be53ccb8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Investors are fleeing tech stocks due to artificial-intelligence worries. But many other sectors of the market look like a good bet.",
                "category": "company",
                "datetime": 1792095180,
                "headline": "AI Stocks Are Hurting. Look at These Other Sectors for Protection."
              },
              {
                "id": 142922269,
                "url": "https://finnhub.io/api/news?id=c7865f7724923f82ec5f2ffee87e7389c60a2dc5ec98a0c9ffd0eb37e2d969ae",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Investors are pricing Merck (MRK) stock at 5.5 times sales, compared with 3.1 for the S&P 500. Shareholders paying that premium need to understand exactly what they hold, and the drugmaker's priorities have changed. During the fiscal Q4 2024 call in February 2025, executives noted that conditions for the GARDASIL vaccine in China remained challenging. By the August 4, 2026 call, management emphasized something else. So what does management talk up now.",
                "category": "company",
                "datetime": 1792093589,
                "headline": "How Has Merck's Story Changed?"
              },
              {
                "id": 142921387,
                "url": "https://finnhub.io/api/news?id=d354ceae5bd17c60de9d2be01a6d7f7ab88d2948dad79a1837d27e89a76c5d33",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Yahoo Finance Markets and Data Editor Jared Blikre takes a closer look at the latest market and sector action, highlighting what the sell-off in CoreWeave (CRWV) and chip stocks means for the rest of the market.",
                "category": "company",
                "datetime": 1792093585,
                "headline": "As chip stocks fall, investors are turning elsewhere in the market: Chart of the Day"
              },
              {
                "id": 142921419,
                "url": "https://finnhub.io/api/news?id=8f0d78d8d5689e7fbdbb1090314c843e5e4db03b72a98e036f4960d0e46006f5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (NYSE:MRK) plans to unveil first-time pivotal Phase 3 oncology data at ESMO 2026, including melanoma and endometrial cancer trials. The company will share late-breaking results from multiple oncology pipeline programs that extend beyond its currently marketed cancer therapies. Merck is pairing the scientific presentations with an Oncology Investor Event focused on its next wave of cancer drug candidates and plans. The first-time pivotal Phase 3 oncology results at ESMO 2026 deserve to...",
                "category": "company",
                "datetime": 1792091518,
                "headline": "What Could Merck (MRK) Reveal At ESMO 2026 About Its Oncology Pipeline?"
              },
              {
                "id": 142921152,
                "url": "https://finnhub.io/api/news?id=545db4733871e90a22820d700146d007479454afeb887e72faa3fb5e27048e68",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.",
                "category": "company",
                "datetime": 1792091412,
                "headline": "Discover which dow jones stocks are making waves on Thursday."
              },
              {
                "id": 142921421,
                "url": "https://finnhub.io/api/news?id=81b254992898a9e4132d7630e84ee5558946533c83c364e55f85fdf8c479a470",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Healthcare—particularly equipment and services and pharmaceuticals—offers investors diversification from AI, according to one report.",
                "category": "company",
                "datetime": 1792088040,
                "headline": "Why Healthcare Stocks Are Hot When the AI Trade Runs Cold"
              },
              {
                "id": 142920417,
                "url": "https://finnhub.io/api/news?id=0fcc6a99bb57e8d09d485a37d2e2d7d64a2221923ab8736bdb870d379724be43",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Money is leaving the AI trade and landing in healthcare, but one mRNA name is surging at a pace that leaves its closest peers far behind, and a clinical story from weeks ago may explain why.",
                "category": "company",
                "datetime": 1792083305,
                "headline": "Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher"
              },
              {
                "id": 142920416,
                "url": "https://finnhub.io/api/news?id=e1edfeb2d3d1b855f41641b69760edc6c7630a45db8b820a950c2052acbfe992",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Amgen and Merck both yield around 2.3% and have surged this year, but one of them is paying its dividend out of thin air while the other has a cash cushion that changes the entire income calculus.",
                "category": "company",
                "datetime": 1792082725,
                "headline": "AMGN vs. MRK: Which Pharma Giant’s Dividend Actually Has Room to Grow"
              },
              {
                "id": 142919309,
                "url": "https://finnhub.io/api/news?id=dd209d7cc5c57c1fdbe0bfcb962ee233f615afcc0e3601c6a02d0b34c87dbc45",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Baillie Gifford & Co, an independent investment management firm, released its third-quarter 2026 investor letter for “International Concentrated Growth Strategy”. A copy of the letter can be downloaded here. The strategy outperformed its benchmark in the third quarter of 2026, as strong company-specific developments in biotechnology and digital platforms helped offset weakness in parts of […]",
                "category": "company",
                "datetime": 1792078066,
                "headline": "Merck & Co., Inc. (MRK) Reports Promising Skin Cancer Trial Results for Keytruda and Personalized mRNA Vaccine"
              },
              {
                "id": 142945322,
                "url": "https://finnhub.io/api/news?id=8ed3e6b98969460c0fc7bfbb16db19e96e60d4cb947825faae3b2fcf5d8a1667",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/15/Defensive-Stocks-Puzzle-Utilities-Health.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Concerns about tech companies overspending on AI prompted investors to rotate out of the trade and seek value elsewhere. ",
                "category": "company",
                "datetime": 1792073724,
                "headline": "Nike, Moderna, Walmart Get a Lift as Traders Flee AI Stocks"
              },
              {
                "id": 142945625,
                "url": "https://finnhub.io/api/news?id=f12791c4c64f65bdc761f41f50cf294e6c7568cd4d68f2aa11b60f5b1cd155f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "International Biotechnology Trust Plc (LSE:IBT, OTC:IBITF) portfolio manager Marek Poszepczynski spoke with Proactive's Stephen Gunnion about emerging cancer treatments, upcoming clinical trial catalysts and the trust’s fifth consecutive year of benchmark outperformance. Speaking after a therapeutics conference in Boston, Poszepczynski highlighted developments involving Revolution Medicines, AstraZeneca, Summit Therapeutics and Moderna, with a focus on potential advances in pancreatic cancer, lung cancer and melanoma. He discussed the prospects for Revolution Medicines’ pancreatic cancer treatment, AstraZeneca’s AVANZAR trial and upcoming data from Summit Therapeutics that could challenge Merck’s blockbuster KEYTRUDA. Moderna’s melanoma results also featured, with further data expected to help clarify the treatment’s potential. Poszepczynski said IBT prioritises companies addressing significant unmet medical needs, focusing on treatments that could change clinical practice rather than deliver incremental improvements. He also explained how disciplined portfolio management has helped the trust outperform its benchmark for five consecutive years. This includes selling investments when valuations reach target levels and managing exposure to high-risk clinical trial events. Acquisition activity has also contributed to performance, with Poszepczynski saying more than a quarter of the portfolio was acquired by other companies over the previous year. Watch the full interview for his views on the latest oncology developments, upcoming clinical catalysts and the investment strategy behind IBT’s performance. Visit Proactive's YouTube channel for more biotechnology, healthcare and investment interviews. Don't forget to give this video a like, subscribe to the channel and enable notifications for future content. #InternationalBiotechnologyTrust #IBT #BiotechInvesting #BiotechStocks #Proactive #MarekPoszepczynski #Biotechnology #HealthcareInvesting #Oncology #CancerResearch #ClinicalTrials #Pharmaceuticals #InvestmentTrusts #PortfolioManagement #BiotechInnovation #RevolutionMedicines #SummitTherapeutics #Moderna #AstraZeneca #Merck #Keytruda #DrugDevelopment #InvestmentPerformance",
                "category": "company",
                "datetime": 1792072066,
                "headline": "IBT manager on therapeutics conference, oncology breakthroughs and five years of outperformance"
              },
              {
                "id": 142913914,
                "url": "https://finnhub.io/api/news?id=6ad409edc5845d99345332cecd4ac0d247cc7396d902bc4aa044842c2de7fcee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The Dow Jones index rises Thursday ahead of more inflation data. Nvidia, Micron and AMD sell off on AI fears.",
                "category": "company",
                "datetime": 1792071626,
                "headline": "Stock Market Today: Dow Rises, Nasdaq Tumbles As AI Worries Hit Major Players (Live Coverage)"
              },
              {
                "id": 142915328,
                "url": "https://finnhub.io/api/news?id=b3a8c83dcbe2957ee2b7ef5bda75d1c593820e341cd92a0184bdff2f60f5c80b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Johnson & Johnson (JNJ) stock trades at 29.1 times its earnings over the past twelve months, compared with 22.7 for the S&P 500. Investors paying that premium appear to be counting on more growth. The company raised its 2026 guidance on October 13, and Chief Executive Joaquin Duato pointed to one new product as one of its most transformative MedTech innovations. So which product is it.",
                "category": "company",
                "datetime": 1792069769,
                "headline": "Where Could Johnson & Johnson's Next Growth Come From?"
              },
              {
                "id": 142914091,
                "url": "https://finnhub.io/api/news?id=8050d0fb56e874bfe36f92adcec961a5cef1c04ef7a04d0718b18aa317f99178",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna has surged more than 650% this year on cancer vaccine excitement, but analyst targets sit far below the current share price. Before you chase the rally, there are some uncomfortable numbers you need to see first.",
                "category": "company",
                "datetime": 1792066848,
                "headline": "Moderna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too Late to Get In?"
              },
              {
                "id": 142916390,
                "url": "https://finnhub.io/api/news?id=250f1b4bc486c7a38cc4ac6f6504cad4456b03bbbedb9cebdcd617a4bbd4c39b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
                "category": "company",
                "datetime": 1792065608,
                "headline": "Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock"
              },
              {
                "id": 142945157,
                "url": "https://finnhub.io/api/news?id=294a216817942afe6103c7aa12a4cb1690de64bea2ea80630f7af70f64ef1cda",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/15/Stock-Market-Trading-Chart-And-Analyzing.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Seven sectors are higher and four are lower in Thursday’s regular session, with defensive sectors holding two of the top three positions. The leaders are separated rather than clustered, with Health Care sitting well above the next group.",
                "category": "company",
                "datetime": 1792062572,
                "headline": "Defensives Lead Sectors In Thursday Trading As Technology Trails"
              },
              {
                "id": 142912656,
                "url": "https://finnhub.io/api/news?id=d805b7dc131780ee28881ee734acf8fc6197a6217c18c94c705090899557bd20",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "As we enter the spooky season markets got an early fright as the tech stocks rotation accelerated alongside the fallout from a hot inflation reading.",
                "category": "company",
                "datetime": 1792062140,
                "headline": "AI Fears Grip Markets as Tech Rotation Accelerates"
              },
              {
                "id": 142908410,
                "url": "https://finnhub.io/api/news?id=0426b8be00008e7c7b980b760bea372369be2a84dc0c5cbb6c7c335ebe0e200c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "As we enter the spooky season markets got an early fright as the tech stocks rotation accelerated alongside the fallout from a hot inflation reading.",
                "category": "company",
                "datetime": 1792055346,
                "headline": "AI Fears Grip Markets as Scary Tech Rotation Accelerates"
              },
              {
                "id": 142905234,
                "url": "https://finnhub.io/api/news?id=7d8c4f5e9906d8daf56691e3b6df0f1fb2257add117c1a699f2860e2809ea2c2",
                "image": "https://www.chartmill.com/images/uploads/thumbnail_article_luc_kroeze_c1f44c837d.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Merck & Co. (MRK) quality investing analysis: strong ROIC, cash conversion, low debt/FCF, but revenue growth misses Caviar Cruise screen.",
                "category": "company",
                "datetime": 1792053086,
                "headline": "Merck & Co. (NYSE:MRK): A Quality Investing Case With Strong ROIC but Revenue Growth Concerns"
              },
              {
                "id": 142904852,
                "url": "https://finnhub.io/api/news?id=2207e6c4cebd8214810f97bad4d72147d15d8cfb1d750d8531729e492dec4984",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_20_d1d9e6697d.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Hotter September inflation revived Fed hike bets and a Gartner warning crushed AI neoclouds. Pharma caught a bid, BlackRock hit a record, BofA got fined.",
                "category": "company",
                "datetime": 1792050932,
                "headline": "Stock Market Today: Hot Inflation and a Neocloud Shakeout Sink the Nasdaq"
              },
              {
                "id": 142902342,
                "url": "https://finnhub.io/api/news?id=9d68f92c16833503339ea5d5df75459423360a1508a93c70603f4b8b209e8fdf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Eli Lilly (LLY:NYSE) stock rose roughly 4% on Wednesday, October 14, joining a broad rally in healthcare stocks. No major Lilly news drove it.",
                "category": "company",
                "datetime": 1792029766,
                "headline": "Why Eli Lilly Became Wall Street’s Safe Haven on a Hot CPI Day"
              },
              {
                "id": 142894617,
                "url": "https://finnhub.io/api/news?id=a15dbaf0ec5913d78ad6dd47f8be522dd0a51efa769661f4a206c2f7086f658e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Over the past month, shares of Liquidia (LQDA) have lost 59%, even as the S&P 500 gained 2.5%. Reuters reported that the stock dropped nearly 50% on September 30 after a federal judge ruled that Yutrepia, Liquidia's inhaled lung drug, infringes a United Therapeutics patent. Liquidia subsequently settled all pending litigation with United Therapeutics on October 13, stating that Yutrepia will remain available to patients with PAH without disruption. If the wider market sells off from here, how mu",
                "category": "company",
                "datetime": 1792028830,
                "headline": "How Much Downside Is Left In Liquidia Stock?"
              },
              {
                "id": 142889244,
                "url": "https://finnhub.io/api/news?id=434733031d20fe4cdc19bc79cf48d12b65f1d04ad018b78d4055f1173b8c98bb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Regeneron Pharmaceuticals (REGN) may get its next boost from an old deal rather than a new drug. Through the first half of 2026, Regeneron was paying down a balance owed to its partner Sanofi. This obligation reduced the revenue Regeneron reported from the partnership. So what does Regeneron gain now that the balance is paid off.",
                "category": "company",
                "datetime": 1792014348,
                "headline": "What Could Send Regeneron Stock Higher?"
              },
              {
                "id": 142887223,
                "url": "https://finnhub.io/api/news?id=0da62e5b5741f2c815f6c9d71ebb7308149769088a6488e233b3825b4510e5a1",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Wednesday.",
                "category": "company",
                "datetime": 1792005015,
                "headline": "Discover which dow jones stocks are making waves on Wednesday."
              },
              {
                "id": 142887222,
                "url": "https://finnhub.io/api/news?id=0b7c292179b56ca652306005b9567d0a0523eab678139849606472987ea2e20f",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.",
                "category": "company",
                "datetime": 1792004701,
                "headline": "Top S&P500 movers in Wednesday's session"
              },
              {
                "id": 142887437,
                "url": "https://finnhub.io/api/news?id=19b85bc72b748e5c4f9df4d280603355fd2cbda4b56f2bfe016353e892bc2ed5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Shares of Lilly, the world’s largest pharmaceutical company by market value, rallied above their 50-day moving average to mark their best level since August.",
                "category": "company",
                "datetime": 1791999180,
                "headline": "Lilly, Merck, AbbVie Stocks Surge. Why Healthcare Is Rallying Today."
              },
              {
                "id": 142886483,
                "url": "https://finnhub.io/api/news?id=d8d9b22cb29f080cb5db8434b1c01f2ee57596e9baf41fa5ccfc107115e9db22",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Phanes Therapeutics, Inc. (Phanes), a clinical-stage biotech company focused on innovative drug discovery and development in immuno-oncology (IO), announced that the first patient has been dosed in the clinical study of spevatamig for the treatment of colorectal cancer (CRC).",
                "category": "company",
                "datetime": 1791998520,
                "headline": "Phanes Therapeutics announces first patient with colorectal cancer (CRC) dosed in clinical study of spevatamig"
              },
              {
                "id": 142885917,
                "url": "https://finnhub.io/api/news?id=0e4a0f899d47f594522938c4a59506903cbb4ca15d3de14660f12bd82568ba62",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Curious about the top performers within the dow jones index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.",
                "category": "company",
                "datetime": 1791996018,
                "headline": "These dow jones stocks are moving in today's session"
              },
              {
                "id": 142885916,
                "url": "https://finnhub.io/api/news?id=b622cb959cbffaf6a3f606c989db14bb104d90fd68454f6db70586c3daa7cf5d",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.",
                "category": "company",
                "datetime": 1791995703,
                "headline": "Exploring the top movers within the S&P500 index during today's session."
              },
              {
                "id": 142885199,
                "url": "https://finnhub.io/api/news?id=8719c4b8e9632570b216f01e32f4bd5f253af404e968afa86404db29c4b76bf5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Verastem plans to raise $250 million as it prepares for late-stage testing of its experimental cancer treatment.",
                "category": "company",
                "datetime": 1791990840,
                "headline": "Verastem Gets a New CEO, $250M, and a Shot at Another Cancer Drug"
              },
              {
                "id": 142885198,
                "url": "https://finnhub.io/api/news?id=8fe4192fca1e3129d408489e0653fb7f18bb59e735badf4ccd9ef4299f943ff5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "MRK's Keytruda sales growth, earlier-stage launches and expanded indications could boost Q3 results, but biosimilar competition looms in 2028-2029.",
                "category": "company",
                "datetime": 1791985560,
                "headline": "Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings?"
              },
              {
                "id": 142920055,
                "url": "https://finnhub.io/api/news?id=c20bc01ad92bbec524b042a4c2325833e087a07d5bb9281dcc25947021a3ff5f",
                "image": "https://image.cnbcfm.com/api/v1/image/107370990-1707414387296-gettyimages-1995499516-247a0388_agtnstai.jpeg?v=1736898742&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "His comments come after Merck officially opened its new 120,000-square-foot research facility in the Greater Philadelphia area.",
                "category": "company",
                "datetime": 1791984260,
                "headline": "Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make"
              },
              {
                "id": 142882662,
                "url": "https://finnhub.io/api/news?id=d176bc9314d31815c8a35626825fee4c62b329256c1456a4ff8d495e8ab5941c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Retirees watching CD rates scrape bottom and Treasury coupons lock in for a decade have a third option hiding in plain sight inside the Dow Jones Industrial Average, and it requires owning just six stocks.",
                "category": "company",
                "datetime": 1791983740,
                "headline": "How to Turn $500,000 Into a Lazy $16,500 Yearly Passive Income Stream"
              },
              {
                "id": 142882629,
                "url": "https://finnhub.io/api/news?id=e7ee454d06681d6eed59a914146d59e967214b8f3d686043bbcc75da682651e9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Johnson & Johnson (JNJ) has introduced several new drugs recently, and current buyers of its stock may be betting on their commercial success. The lineup includes ICOTYDE, an oral treatment for plaque psoriasis. The company has yet to disclose sales figures for the medication. How much the drug can ultimately add to J&J remains an open question. Anyone purchasing shares today takes on that unknown before the answer is in.",
                "category": "company",
                "datetime": 1791980295,
                "headline": "The Open Question Under Johnson & Johnson Stock's Price"
              },
              {
                "id": 142886104,
                "url": "https://finnhub.io/api/news?id=36c0b16bde95b087b95de8f014fc4fdc889a533485ab051c10452a1c15386c4a",
                "image": "https://image.cnbcfm.com/api/v1/image/108409338-17919943501791994347-48997169847-1080pnbcnews.jpg?v=1791994349&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "CNBC’s Annika Kim Constantino sits down with Merck Chairman and CEO Rob Davis to discuss the company’s new manufacturing site in Pennsylvania, what’s ahead in the pipeline, and more.",
                "category": "company",
                "datetime": 1791980263,
                "headline": "Merck CEO Davis on new manufacturing site: Will meaningfully accelerate getting drugs to patients"
              },
              {
                "id": 142915760,
                "url": "https://finnhub.io/api/news?id=96ad35f5ef177e04917a658689de84478274bbf6edf6e6f298c9a08636fefbf6",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/14/Nasdaq-100-way-down.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "The Nasdaq 100 fell 1% by midday Wednesday after September CPI topped forecasts, pushing Treasury yields and rate-hike bets higher.",
                "category": "company",
                "datetime": 1791977994,
                "headline": "Nasdaq 100 Drops 1% on Hot CPI, SOXX Falls 7th Day: Stock Market Today"
              },
              {
                "id": 142872380,
                "url": "https://finnhub.io/api/news?id=4401f90ee65b7b8c7cf68a6190972a080c7b47a22120ce5180363deb66864b84",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Boost ROI with modular, customized systems that scale flexibly, cut cleaning and contamination costs, speed fill-finish, and localize sourcing to reduce tariff and supply-chain risks.Dublin, Oct. 14, 2026 (GLOBE NEWSWIRE) -- \"Single-Use Assemblies Market Report 2026\" has been added to ResearchAndMarkets.com's offering. The global single-use assemblies market is experiencing rapid growth, driven by expanding biopharmaceutical manufacturing, increased investment in life sciences research and devel",
                "category": "company",
                "datetime": 1791965340,
                "headline": "Single-Use Assemblies Global Market Report 2026-2030 | Capitalize on 22.8% CAGR as Thermo Fisher, Danaher, Sartorius, Merck, and Avantor Scale Modular Bioprocessing"
              },
              {
                "id": 142869843,
                "url": "https://finnhub.io/api/news?id=310ef25895cc39730bc02d53261c2e29cfcc1b7eb4f0498474d0e9c56b8614e8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1196086989/image_1196086989.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Visible Alpha consensus expects the Dow Jones Industrial Average to deliver an 18.7% weighted price return in the medium term. Read more here.",
                "category": "company",
                "datetime": 1791948000,
                "headline": "Dow Jones Industrial Average Monitor Update - A Look At 30 U.S. Large-Caps"
              },
              {
                "id": 142863633,
                "url": "https://finnhub.io/api/news?id=665574b8058cde2b5067dd46833eaa55061274b0b8fc99598cde8e7ec9e4d68c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The J&J selloff shows how medtech weakness can outweigh pharma strength, and what it means for healthcare stocks.",
                "category": "company",
                "datetime": 1791940069,
                "headline": "J&J Selloff Exposes Medtech Strain: Is Pharma Carrying Healthcare Stocks?"
              },
              {
                "id": 142856069,
                "url": "https://finnhub.io/api/news?id=19ddbf443d05e538002ed8fb8a4b92ac9ed26efb14a4416a1787066e2d586672",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Amgen (AMGN) competes in a tight peer group of six large drugmakers alongside AbbVie, Johnson & Johnson, Merck, Pfizer, and Bristol-Myers Squibb. The company ranks second within this group for both sales growth and operating margin. Its valuation tells a different story. Leaving out Merck and Pfizer, which each reported a loss in at least one of their last four quarters, Amgen has the third highest P/E of the four companies that can be compared. So how far apart are what Amgen delivers and what",
                "category": "company",
                "datetime": 1791935331,
                "headline": "Is Amgen Stock Worth More Than Its Competitors?"
              },
              {
                "id": 142855362,
                "url": "https://finnhub.io/api/news?id=709e4c1c56db9af26929fee270729dc8a764c0444d13b548cf0efc9a894e3fac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "BMO Capital Markets analyst Evan David Seigerman said that the PFS miss for BNT113 “adds to a growing list of recent mRNA cancer vaccine setbacks” and is likely to pressure the stock.",
                "category": "company",
                "datetime": 1791933271,
                "headline": "BNTX Stock Selloff Deepens Doubts: BMO Ties BNT113 Miss To Wider mRNA Cancer Vaccine Struggles"
              },
              {
                "id": 142854484,
                "url": "https://finnhub.io/api/news?id=46d3388160bf922ff28dc0ffdfea7cf4af9cc49f84ba05a23f08b315ba443b2b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) concluded the recent trading session at $141.98, signifying a -2.39% move from its prior day's close.",
                "category": "company",
                "datetime": 1791924603,
                "headline": "Merck (MRK) Dips More Than Broader Market: What You Should Know"
              },
              {
                "id": 142854423,
                "url": "https://finnhub.io/api/news?id=5bc081dc70d815ffa88823067c5acd0248f42961683e09e9d61876123ee214f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Pfizer (PFE) and Bristol-Myers Squibb (BMY) are bought for the same underlying reason: the search for new drugs to replace older ones losing market exclusivity. Both drugmakers point to 2028 as the year that matters. Pfizer is acquiring drugs and cutting costs to bridge the gap, while Bristol Myers still relies on Eliquis, an older drug that continues to grow. So what did each company tell investors at its latest report about how that replacement is going.",
                "category": "company",
                "datetime": 1791921571,
                "headline": "What Does Bristol-Myers Squibb Offer That Pfizer Does Not?"
              },
              {
                "id": 142853444,
                "url": "https://finnhub.io/api/news?id=d3c9a96d4f639435dd81c82294ec2c31c03002bcc1a4f295b7f7efba4bcca128",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Investors are currently valuing Eli Lilly (LLY) stock at a premium, with shares priced at 39.5 times earnings compared with 21.9 for the S&P 500. Justifying that multiple may require sustained growth, yet most of Lilly's sales still come from the company's two dominant blockbusters, Zepbound and Mounjaro. The pharmaceutical maker has a newer drug on sale and expects to launch it in all major markets worldwide in 2027. So what is the new drug, and is it selling.",
                "category": "company",
                "datetime": 1791919463,
                "headline": "What Is Eli Lilly Stock's Biggest Opportunity?"
              },
              {
                "id": 142853114,
                "url": "https://finnhub.io/api/news?id=239f1ec0bd6003c75b83346777ebb77ec584c75f68f4c78fd3f43f5a7e2d2574",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Tuesday.",
                "category": "company",
                "datetime": 1791918616,
                "headline": "Explore the top gainers and losers within the dow jones index in today's session."
              },
              {
                "id": 142853459,
                "url": "https://finnhub.io/api/news?id=f00b1416751b9b599ae572eb41364da8c22e0580d73153052166dba042a60169",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "A decent day for the Dow has completely flipped on its head.",
                "category": "company",
                "datetime": 1791913295,
                "headline": "Here’s What’s Dragging Down the Dow"
              },
              {
                "id": 142852471,
                "url": "https://finnhub.io/api/news?id=69df73ce666e8a3721fe511dbc01de11fb7e86bdd2db9119f0a1969d817e5ffd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck & Co., Inc. (NYSE:MRK) closed at $145.45 on October 12. The stock has returned 21% during the last six months, compared to a 21.25% return for the Insider Monkey Billionaire Index and 14% for State Street SPDR S&P 500 ETF Trust. A company that keeps three-quarters of its revenue as gross profit does not […]",
                "category": "company",
                "datetime": 1791913155,
                "headline": "Merck (MRK) Reports a Negative Operating Margin and Pays Out 266% of Earnings. What Explains Both?"
              },
              {
                "id": 142851845,
                "url": "https://finnhub.io/api/news?id=40d2c5297662fe6576264f21cdd4db7fc189e73028158a4128a0960d9c568eed",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Curious about the dow jones stocks that are in motion on Tuesday? Join us as we explore the top movers within the dow jones index during today's session.",
                "category": "company",
                "datetime": 1791909615,
                "headline": "Discover which dow jones stocks are making waves on Tuesday."
              },
              {
                "id": 142852438,
                "url": "https://finnhub.io/api/news?id=2f7e6a4106618c1f9aebd240ec47c2298e1504969996f67b0e0a0d005c1b1e92",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Johnson & Johnson stock is tumbling even after the healthcare giant raised its forecast again for full-year earnings and revenue.",
                "category": "company",
                "datetime": 1791908090,
                "headline": "Johnson & Johnson stock falls despite strong earnings as investors focus on medtech unit"
              },
              {
                "id": 142852473,
                "url": "https://finnhub.io/api/news?id=6b21e6d6c4732e7a67790e1e6e449fd073688cead4236626d21f7078a99457d4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "BioNTech’s experimental cancer treatment combined with Merck’s Keytruda failed to significantly delay disease progression compared with Keytruda alone.",
                "category": "company",
                "datetime": 1791907298,
                "headline": "BioNTech’s Cancer Drug Misses A Key Trial Goal – Citi Says Survival Data Could Preserve ‘A Meaningful Development Path’"
              },
              {
                "id": 142852474,
                "url": "https://finnhub.io/api/news?id=288e96a0f39976996dc6855674ee391f80bb8691dcb257d54e15af7043c4f3ef",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna gains $4.2 billion in a week on cancer-vaccine optimism and Nasdaq-100 inclusion. Can its growth prospects justify its premium valuation?",
                "category": "company",
                "datetime": 1791903660,
                "headline": "MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell?"
              },
              {
                "id": 142854485,
                "url": "https://finnhub.io/api/news?id=90699db26ee41ba519a3ebf20113b59d1fa32059d45a9e62184305dd4a5815bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck & Co. is set to release its third-quarter earnings in a couple of weeks, and analysts are expecting its EPS to grow by a single digit.",
                "category": "company",
                "datetime": 1791900249,
                "headline": "Here's What to Expect From Merck & Co.'s Next Earnings Report"
              },
              {
                "id": 142848728,
                "url": "https://finnhub.io/api/news?id=4ff718c0d17dfa447f9637b4c4aecc5e4e89c933ebad91449ca247f2ad041a9e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Vertex raised its full-year outlook in Q2 with a growing pipeline across multiple disease areas. Moderna’s mRNA flu vaccine just cleared a key FDA hurdle with an expanding oncology pipeline behind it.",
                "category": "company",
                "datetime": 1791895025,
                "headline": "Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142883908,
                "url": "https://finnhub.io/api/news?id=3a6c38d27c9f04424231f632b23afcfa088ae4c98ed397fdaa1941ae20cca5b7",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/13/Biontech.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "BioNTech stock drops over 5% as BNT113 mRNA cancer trial misses PFS endpoint. Focus shifts to overall survival in HPV16+ HNSCC study.",
                "category": "company",
                "datetime": 1791893169,
                "headline": "Why Is BioNTech Stock Falling Tuesday?"
              },
              {
                "id": 142848664,
                "url": "https://finnhub.io/api/news?id=d6cc5a18341120b4042d9c7782d95ce246363cae42d5930c60a8044f46d2e33f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Biotech stocks have slumped from their August highs. But experts say renewed M&A, likely coming, could catalyze them.",
                "category": "company",
                "datetime": 1791892852,
                "headline": "Why A Biotech M&A Wave May Hit This Winter"
              },
              {
                "id": 142848693,
                "url": "https://finnhub.io/api/news?id=7080d2487b8b3fdcccce025d594bca2057f3180dcc75b63ffdae05b01fe4c4a6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Johnson & Johnson says it is working to improve results in its medical-device business, where surgery revenue fell for the latest quarter.",
                "category": "company",
                "datetime": 1791890940,
                "headline": "Can a Spinoff Fix Johnson & Johnson’s Medtech Problem?"
              },
              {
                "id": 142847438,
                "url": "https://finnhub.io/api/news?id=5ca427a413013f1310f27e9da9e339f0b0d66ee91b221c2ffe3c120e660d15d5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Johnson & Johnson says it is working to improve results in its medical-device business, where surgery revenue fell for the latest quarter.",
                "category": "company",
                "datetime": 1791890940,
                "headline": "Johnson & Johnson Hikes Earnings Guidance but Pharma Growth Masks a MedTech Stumble. Stock Falls."
              },
              {
                "id": 142847467,
                "url": "https://finnhub.io/api/news?id=739ec2644fea5e42215f3479376942385b828c9d5f31007cdd88ea280b160599",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "RAHWAY, N.J., October 13, 2026--Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors",
                "category": "company",
                "datetime": 1791889320,
                "headline": "Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors"
              },
              {
                "id": 142850826,
                "url": "https://finnhub.io/api/news?id=b28ee841bb547fcc26557c569a6277ea410bc5cb494ceea2f398caae2601e85a",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/13/Charts-Of-Financial-Instruments-With-Var.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Four sectors are higher and seven are lower in Tuesday’s regular session, with cyclical sectors holding two of the top three positions. Materials sits well clear of the lower group, separated by a margin several times wider than any other gap in the table.",
                "category": "company",
                "datetime": 1791889260,
                "headline": "Cyclicals Lead Sectors In Tuesday Trading As Health Care Trails"
              },
              {
                "id": 142847441,
                "url": "https://finnhub.io/api/news?id=262c13b238ce81163c22a26f3f6904aabad4e33a7e58302516fa88e16ef4eacb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Johnson & Johnson (JNJ) delivered earnings and revenue surprises of +2.37% and -0.15%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1791888302,
                "headline": "Johnson & Johnson (JNJ) Q3 Earnings Surpass Estimates"
              },
              {
                "id": 142847468,
                "url": "https://finnhub.io/api/news?id=3821e00c82972b755e611b671b06a10f68f3ab3b9ef5d049856faf7ea1ef9bac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "RAHWAY, N.J., October 13, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that first-time results from three pivotal clinical trials will be presented during late-breaking Presidential Symposia at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain from Oct. 23-27. Additionally, more than 90 additional abstracts across more than 20 tumor types from the company’s pipeline and portfolio will be presented throughout the meet",
                "category": "company",
                "datetime": 1791888300,
                "headline": "Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026"
              },
              {
                "id": 142841701,
                "url": "https://finnhub.io/api/news?id=f4d70637a8a925473c7c6e96451318064d5ab55c9f7165a3b5f46fecc06daa61",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Dublin, Oct. 13, 2026 (GLOBE NEWSWIRE) -- \"Cell Culture Market Report 2026\" has been added to ResearchAndMarkets.com's offering. The global cell culture market is experiencing strong growth, supported by expanding life sciences research, increased academic funding and continued development across the biopharmaceutical industry. The market is projected to rise from $31.25 billion in 2025 to $33.81 billion in 2026, representing a compound annual growth rate (CAGR) of 8.2%. Established use of cell",
                "category": "company",
                "datetime": 1791879120,
                "headline": "Global Cell Culture Market Report 2026: Size, Share, Trends and Forecast to 2030 | Capitalize on Biologics and Personalized Medicine with Thermo Fisher, Merck, Lonza and Sartorius"
              },
              {
                "id": 142841702,
                "url": "https://finnhub.io/api/news?id=048f94eeedd8a23075e379daab79f59ab4464f6a0ab20b32513856349eeac805",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Dublin, Oct. 13, 2026 (GLOBE NEWSWIRE) -- \"Protein Labeling Market Report 2026\" has been added to ResearchAndMarkets.com's offering. The global protein labeling market is experiencing rapid expansion, supported by increased investment in proteomics and genomics research, continued advances in labeling technologies, and growing demand for high-performance analytical tools. The market is projected to rise from $2.84 billion in 2025 to $3.13 billion in 2026, representing a compound annual growth ra",
                "category": "company",
                "datetime": 1791879060,
                "headline": "Global Protein Labeling Market Report 2026: Size, Share, Trends, and 2030 Forecast | Capture a $4.89 Billion Market as Thermo Fisher, Merck, Bio-Rad, and Abcam Scale Automation"
              },
              {
                "id": 142840868,
                "url": "https://finnhub.io/api/news?id=7f5119f109fe0a9eb8338385a18b44e5eaab3975df1c4a5a655906a61a893448",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Boost ROI via partnerships, process intensification, single-use systems, modular bioreactors, efficient purification and capacity expansionDublin, Oct. 13, 2026 (GLOBE NEWSWIRE) -- \"Industrial Bioprocessing Market Global Report 2026\" has been added to ResearchAndMarkets.com's offering. The global industrial bioprocessing market is experiencing strong growth as pharmaceutical manufacturers, biotechnology companies and industrial producers invest in scalable, efficient and sustainable production t",
                "category": "company",
                "datetime": 1791878940,
                "headline": "Global Industrial Bioprocessing Market Report 2026: Size, Share, Trends and Forecast to 2030 | Capitalize on 9% CAGR with Thermo Fisher, Danaher, Merck and Sartorius"
              },
              {
                "id": 142839260,
                "url": "https://finnhub.io/api/news?id=3825312775661b828b635daf32007d6b458a28a0c73467be0cf8e9b340e8ea52",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Dublin, Oct. 13, 2026 (GLOBE NEWSWIRE) -- \"Bioprocessing Supplies Market Global Report 2026\" has been added to ResearchAndMarkets.com's offering. The global bioprocessing supplies market is experiencing steady growth as pharmaceutical and biotechnology manufacturers increase production capacity for biologics, biosimilars, vaccines, and other advanced therapies. The market is projected to grow from $10.31 billion in 2025 to $10.73 billion in 2026, representing a compound annual growth rate (CAGR)",
                "category": "company",
                "datetime": 1791878760,
                "headline": "Global Bioprocessing Supplies Market Report 2026: Size, Share, Trends, and Forecast to 2030 | Capitalize on Single-Use Scale with Thermo Fisher, Danaher, Merck, Sartorius"
              },
              {
                "id": 142839190,
                "url": "https://finnhub.io/api/news?id=c3150ce0191b3fdc0ae0bb0ea632db67ddb5b4db34316d71dff82ae5ce8b94d3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Bioconjugation Reagents Market to Reach $3.87 Billion by 2030 as Precision Medicine and Antibody-Drug Conjugate Demand ExpandsDublin, Oct. 13, 2026 (GLOBE NEWSWIRE) -- \"Bioconjugation Reagents Global Market Report 2026\" has been added to ResearchAndMarkets.com's offering. The global bioconjugation reagents market is experiencing strong growth, supported by rising pharmaceutical and biotechnology research and development, expanding diagnostic and molecular imaging applications, and increased inve",
                "category": "company",
                "datetime": 1791878520,
                "headline": "Global Bioconjugation Reagents Market Report 2026: Size, Trends, and Forecast to 2030 | Accelerate ADC and Click Chemistry Growth with Thermo Fisher, Merck, Danaher, and Bio-Rad"
              },
              {
                "id": 142848341,
                "url": "https://finnhub.io/api/news?id=6cd15d85fdb3dc17e479de3d8b1e0bb2cc504560533c3c5e433b9b795a161a13",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that first-time results from three pivotal clinical trials will be presented during late-breaking Presidential Symposia at the",
                "category": "company",
                "datetime": 1791874117,
                "headline": "Merck To Present First-Time Results From Three Pivotal Clinical Trials At ESMO Congress; Data Demonstrate Improvements In Recurrence-Free Survival And Distant Metastasis-Free Survival Versus KEYTRUDA Alone In Patients With Completely Resected Stage IIB-IV Melanoma"
              },
              {
                "id": 142844367,
                "url": "https://finnhub.io/api/news?id=66560ff9f3f37bf54fdf7009dcfee55437ea1d91b6ce9ebd018012482868e7b8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2242072348/image_2242072348.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "From June we saw money rotate out of tech into reflationary sectors, also software, explains Amrita Roy and Uttam Dey. Now, money is moving back into tech.",
                "category": "company",
                "datetime": 1791873000,
                "headline": "S&P Hits All-Time Highs, AI Trade Does All The Work"
              },
              {
                "id": 142832198,
                "url": "https://finnhub.io/api/news?id=d3ea8e257978166d5e746743c7288a47771d0314699386d25faf85b0c5e2d4a8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Key TakeawaysModerna stock surged 14. 2% on October 9 after reports of an NIH-backed initiative to accelerate cancer vaccine development.",
                "category": "company",
                "datetime": 1791858206,
                "headline": "Moderna Stock Soared 14% as NIH Plans COVID-Style Push for Cancer Vaccines"
              },
              {
                "id": 142824554,
                "url": "https://finnhub.io/api/news?id=44630c809357e2f07010f9d4cdb465c71d19dd1f54e2d65b83653012ff28c8ed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna (MRNA) stock has returned 621% over the past twelve months, easily outpacing the S&P 500's 17.0% return. Yet the company's sales have fallen for three consecutive years, and nearly all of that revenue still comes from COVID vaccines. This divergence suggests investors are placing heavy bets on a product Moderna does not sell yet. So what is Moderna getting ready to sell, and how far along is it.",
                "category": "company",
                "datetime": 1791838902,
                "headline": "Where Could Moderna's Next Growth Come From?"
              },
              {
                "id": 142823404,
                "url": "https://finnhub.io/api/news?id=02ccc14928cac6b07e502b3a1349a262b04aa03aacb6c39874473bea74c00ca6",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Curious about the top performers within the dow jones index one hour before the close of the markets on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.",
                "category": "company",
                "datetime": 1791832213,
                "headline": "Uncover the latest developments among dow jones stocks in today's session."
              },
              {
                "id": 142823704,
                "url": "https://finnhub.io/api/news?id=984bfb1d59f4f7391eb1a78f22a944db80d76ae1b13befab7b635efbc22b03e3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (NYSE:MRK) reported one year pivotal Phase 2b/3 data for remigromig in diabetic macular edema, showing non inferior efficacy to a leading anti VEGF therapy. The company described remigromig's safety profile in the trial as manageable, supporting its potential use in diabetic macular edema patients. Management indicated that the late stage data on remigromig supports progress toward potential regulatory discussions for this ophthalmology candidate. The new remigromig trial results...",
                "category": "company",
                "datetime": 1791828462,
                "headline": "Could Merck (MRK) Have A New DME Option After Its Late Stage Trial Data?"
              },
              {
                "id": 142822735,
                "url": "https://finnhub.io/api/news?id=0d838ad684b027caa0cf0df8d0c80c8fb4001955df05b1ec8d509ebe13fd36bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The vaccine maker's stock gained 18% last week after a report on a planned NIH cancer vaccine initiative and its addition to the Nasdaq-100",
                "category": "company",
                "datetime": 1791826428,
                "headline": "Moderna stock surges more than 600% in 2026"
              },
              {
                "id": 142822732,
                "url": "https://finnhub.io/api/news?id=dc400d678e5afb7aec6e1693488e62f662c93be576b78ff8f0f53e7d71d9c2e2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) is back in focus after reporting positive Phase III results from its personalized mRNA cancer vaccine program with Moderna, a development now linked to a planned public private cancer vaccine partnership. Recent headlines around Merck’s mRNA cancer vaccine work sit alongside a busy few weeks that included the SPR2015 KRAS licensing deal, new adult access to CAPVAXIVE in Ontario, and an early trial start using Cyprumed’s oral delivery technology. Against that backdrop, Merck’s...",
                "category": "company",
                "datetime": 1791824861,
                "headline": "Merck (MRK) Could Be 7% Below Fair Value On Phase III Cancer Vaccine Results"
              },
              {
                "id": 142848342,
                "url": "https://finnhub.io/api/news?id=f861ab71f8b92fd24d080eaa34aeb2b3d2e952ac74b67c03efaf385d39fd01e2",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Citigroup  analyst Geoff Meacham   maintains Merck & Co (NYSE:MRK) with a Neutral and raises the price target from $125 to $145.",
                "category": "company",
                "datetime": 1791821868,
                "headline": "Citigroup Maintains Neutral on Merck & Co, Raises Price Target to $145"
              },
              {
                "id": 142822733,
                "url": "https://finnhub.io/api/news?id=15b41b49c1d40ca13043e9423001ccfac1f8804fc0ccb30234095e5f3c8922b0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Jefferies has cut its peak sales forecast for Merck & Co Inc (NYSE:MRK, XETRA:6MK)’s experimental eye treatment remigromig by 60% after detailed trial results raised concerns about its efficacy and safety compared with an established rival. The US pharmaceutical company’s drug met the...",
                "category": "company",
                "datetime": 1791817920,
                "headline": "Jefferies cuts Merck’s remigromig sales forecast after eye-disease trial raises concerns"
              },
              {
                "id": 142821650,
                "url": "https://finnhub.io/api/news?id=5da3845e8880e1b163c09a9039958c5ccb97443572c73a7ab29a55a8ad052c3b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Bristol Myers shares surge 35.8% as its Growth Portfolio and pipeline progress fuel momentum, but generic competition and valuation warrant caution.",
                "category": "company",
                "datetime": 1791816480,
                "headline": "BMY Surges 35.7% in a Year: Should You Buy, Sell or Hold the Stock?"
              },
              {
                "id": 142821651,
                "url": "https://finnhub.io/api/news?id=c9d831442b9c1045fb85a7b44fe95907e600ec62df59c720cb57891bfd1f67cb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "TEM is expanding its precision medicine footprint through strategic collaborations with Moderna, Merck and Recursion, paving the way for future revenue growth.",
                "category": "company",
                "datetime": 1791816360,
                "headline": "Tempus AI Expands Strategic Collaborations to Drive Future Growth"
              },
              {
                "id": 142821652,
                "url": "https://finnhub.io/api/news?id=1d256551eb6855fe5613b6462f6afe2fd779b9bd9aba8f8ba545910b1137d5a1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "MRNA, BNTX and NVAX shares rally after reports of a planned NIH-backed initiative to accelerate personalized cancer vaccines and expand research funding.",
                "category": "company",
                "datetime": 1791814320,
                "headline": "Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines"
              },
              {
                "id": 142819954,
                "url": "https://finnhub.io/api/news?id=ec8c05f655081170b90fe3cdc14120dd3b5c5d983adf90e870af31d8adeb868d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Based on the average brokerage recommendation (ABR), Merck (MRK) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?",
                "category": "company",
                "datetime": 1791808204,
                "headline": "Wall Street Bulls Look Optimistic About Merck (MRK): Should You Buy?"
              },
              {
                "id": 142822734,
                "url": "https://finnhub.io/api/news?id=4ee58cafef99d236ad14db8eda9642068fbbd06b5a1ed8694ad2ed1c57121250",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Bausch and Brent Saunders “mutually agreed” on his exit from the company, according to a statement. Elsewhere, Tezspire could have a new edge on Dupixent and a recent buyout deal paid dividends.",
                "category": "company",
                "datetime": 1791806940,
                "headline": "Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data"
              },
              {
                "id": 142819092,
                "url": "https://finnhub.io/api/news?id=01dff681fb097544aea2c0c9b86433efdb69ea47efd735d0cf701250b550a029",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Skyrizi and Rinvoq are growing fast, a blockbuster acquisition just closed, and the FDA handed AbbVie a fresh approval, yet the stock sits just shy of a price target that has Wall Street divided between a $297 bull case and a $246 bear case.",
                "category": "company",
                "datetime": 1791803709,
                "headline": "Prediction: AbbVie’s Next Billion-Dollar Opportunity Is Taking Shape"
              },
              {
                "id": 142848343,
                "url": "https://finnhub.io/api/news?id=86b38a7790848e8251456938d4f83b396176e9f4a78ec73750a8e937d81a6e55",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "RBC Capital  analyst Trung Huynh   maintains Merck & Co (NYSE:MRK) with a Sector Perform and lowers the price target from $150 to $145.",
                "category": "company",
                "datetime": 1791800636,
                "headline": "RBC Capital Maintains Sector Perform on Merck & Co, Lowers Price Target to $145"
              },
              {
                "id": 142819667,
                "url": "https://finnhub.io/api/news?id=7a635c49ac41617cd1ad673f2d4a6c50cf6070ab530de9320081ef1197b68a98",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/12/Doctors--Tablet-And-People-With-Discussi.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Palantir CTO Shyam Sankar calls AI doomsday predictions theological, while warning that extreme optimism amounts to ‘mass psychosis,'",
                "category": "company",
                "datetime": 1791795613,
                "headline": "Palantir CTO Says Some AI Researchers Are So Sure It Will Cure Cancer They’ve Started 'Smoking' — Warns Both AI Extremes Reflect ‘Social Delusion’"
              },
              {
                "id": 142813851,
                "url": "https://finnhub.io/api/news?id=4386c3714e9d5ed99e667d07d0a8efa19124981b9eca4216d71d3ab9646e0b61",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.",
                "category": "company",
                "datetime": 1791790023,
                "headline": "3 Profitable Stocks We Approach with Caution"
              },
              {
                "id": 142819668,
                "url": "https://finnhub.io/api/news?id=99434cce829fc22f2fec5d8aa6a330985e5f0d6f9f7ce48d33775dc15d6b2ee2",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/12/Stephen-King-at-New-York-Comic-Con.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Stephen King slammed Trump’s incoming press secretary over her vaccine conspiracy theories and controversial posts.",
                "category": "company",
                "datetime": 1791781934,
                "headline": "Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…'"
              },
              {
                "id": 142819726,
                "url": "https://finnhub.io/api/news?id=d6157e6bfc19f0715ef591d0abb2c32800dcc8d9118cdafdeb425d6cf6dc6bae",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Remigromig demonstrated non-inferiority in mean change from baseline in best corrected visual acuity versus ranibizumab at one year in patients with diabetic macular edema (DME)Remigromig is the first biologic with a",
                "category": "company",
                "datetime": 1791777778,
                "headline": "Reported Saturday, Merck’s Remigromig Delivers Mean BCVA Gains Of 9.1 Letters At 0.5 Mg And 8.7 Letters At 0.8 Mg Versus 11.8 For Ranibizumab, Meeting Non-Inferiority, With No Secondary Endpoint Showing Superiority"
              },
              {
                "id": 142810093,
                "url": "https://finnhub.io/api/news?id=98c661ed0ff45874a7168ff5b1c6dc60fcb3a928f3e7f81d04a689c19ab0abc4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The ASH meeting runs Dec. 12-Dec. 15 in New Orleans. Sellas is listed at Booth 138, and more than 275 exhibitors are expected.",
                "category": "company",
                "datetime": 1791768132,
                "headline": "SLS Stock Jumps Overnight: Retail Sees Big Pharma Buyout Clues In 'M&A Negotiation Lounge' Booth At ASH"
              },
              {
                "id": 142806466,
                "url": "https://finnhub.io/api/news?id=750e4840a1e14a004c765e5b1dc9defbcde64a331db5bdcdbb9bed1c4b5d1a5b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Key Stats for Merck StockCurrent Price: $145. 60Target Price (Mid): ~$164Street Target: ~$158Potential Total Return: ~13%Annualized IRR: ~3% / yearWhat Happened?Merck (MRK) closed at $145.",
                "category": "company",
                "datetime": 1791730851,
                "headline": "Merck Stock Is Up 38% in 2026 as Investors Pay More for Flat Near-Term Earnings. Here’s Where the Stock Could Go by 2030"
              },
              {
                "id": 142795832,
                "url": "https://finnhub.io/api/news?id=4324a077ff4a72a38f2d5f3780564f0c42d186f4763ee7da222becfe6f97e70b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna stock is up 663% in 2026, beating AI names for the S&P 500 lead. Full cancer vaccine data arrives October 24.",
                "category": "company",
                "datetime": 1791671034,
                "headline": "A COVID Vaccine Stock on the S&P 500 Is Up 600% This Year"
              },
              {
                "id": 142795831,
                "url": "https://finnhub.io/api/news?id=4fd7305addbfeffef70f03362a44d936449c5d3346132c1cb3625ad72b2382f7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "RAHWAY, N.J., October 10, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of one-year results from the pivotal Phase 2b/3 BRUNELLO trial evaluating remigromig (MK-3000, formerly EYE103), an investigational, potentially first-in-class tetravalent, tri-specific antibody designed to activate the Wingless-related integration site (Wnt) pathway, for the treatment of diabetic macular edema (DME). Results were presented today at the",
                "category": "company",
                "datetime": 1791670200,
                "headline": "Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026"
              },
              {
                "id": 142774667,
                "url": "https://finnhub.io/api/news?id=39a6aea63f3556d27c0aa2dd07c6cebceb5377fa500139cc0ac30c609eb4924d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck has been one of the stronger performers in big pharma over the past few years, and with the stock recently around US$145.60, the real issue for investors is whether that climb is still grounded in the cash the business can generate. The current price now sits against a backdrop of heavy investment, looming patent expiries and fresh clinical results that all feed directly into Merck's future cash flow profile. Merck shares are up 116.6% over five years, which puts a lot of past optimism...",
                "category": "company",
                "datetime": 1791598429,
                "headline": "Merck (MRK) Stock Trades Below Fair Value Despite Its 117% Run"
              },
              {
                "id": 142791541,
                "url": "https://finnhub.io/api/news?id=2e3fc18273d0313408985b49d17e646e670649022a16be256bd517845bce243e",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/10/Flags-Of-China-And-Usa-Painted-On-Cracke.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "John Moolenaar asks the US Defense Department to add 58 Chinese schools and 62 technology labs to its research funding restrictions list.",
                "category": "company",
                "datetime": 1791597257,
                "headline": "John Moolenaar Urges Defense Department to Add 120 Chinese Schools and Tech Labs to US Research Funding Watchlist"
              },
              {
                "id": 142772223,
                "url": "https://finnhub.io/api/news?id=d7341b07311e0a7aadb936df0d126442fa321eed83f51e517867f131ac1fb044",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Gilead Sciences (GILD) generated free cash flow equal to 7.1% of its market value over the last twelve months. The median S&P 500 company yielded just 4.5% over the same period. A yield that high means one of two things: the business is either trading at a steep discount, or the market expects it to shrink. So why are investors paying so little for Gilead's cash.",
                "category": "company",
                "datetime": 1791593224,
                "headline": "Why Is Everyone Ignoring Gilead Stock's High Cash Yield?"
              },
              {
                "id": 142769670,
                "url": "https://finnhub.io/api/news?id=9d3295f3bb1adffe88e68237811e5227ae5d48cec72684a1c0f63434b017580a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "National Cancer Institute’s director, Dr. Anthony Letai, wants a national effort behind the vaccines, The New York Times reported on Friday.",
                "category": "company",
                "datetime": 1791590964,
                "headline": "BNTX, NVAX, MRNA Lead Vaccine Rally After Report Of An NIH Cancer-Vaccine Push"
              },
              {
                "id": 142767148,
                "url": "https://finnhub.io/api/news?id=317e2a4ac9bd7cae9e89e143d2b9dc3ccea939aa2979a3895e46147f424bc6e3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index up 1.2% and the State S",
                "category": "company",
                "datetime": 1791575829,
                "headline": "Sector Update: Healthcare Stocks Gain Late Afternoon"
              },
              {
                "id": 142773141,
                "url": "https://finnhub.io/api/news?id=d751c85017e1302e416e6bb9ec54f81278330dd63ea7b9a76ca4adb0a9fcdc1a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna stock gains on reports of an initiative to accelerate cancer vaccine development. Here’s why caution is warranted in playing MRNA shares at current levels.",
                "category": "company",
                "datetime": 1791573430,
                "headline": "Moderna Stock Skyrockets on Reports of U.S. Cancer Vaccine Initiative"
              },
              {
                "id": 142765954,
                "url": "https://finnhub.io/api/news?id=e8e3b8da2da0d6ae4d9558e72857a3ca0885d2701f5b383c0d396564a0c319c7",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Friday.",
                "category": "company",
                "datetime": 1791573008,
                "headline": "Friday's session: top gainers and losers in the dow jones index"
              },
              {
                "id": 142766263,
                "url": "https://finnhub.io/api/news?id=8ec035baab86cf7792f8c473ed9d920f88a6b869215a9474bf070dbaea0125ad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) stock returned 69.6% over the year to October 8, 2026, against 16.3% for the S&P 500. The gain built up over a year of drug approvals and clinical trial results, arriving just as the company prepares for the patent loss on Keytruda, its top-selling drug. So what did Merck show investors over those twelve months.",
                "category": "company",
                "datetime": 1791569538,
                "headline": "Does The Move In Merck Stock Change Anything?"
              },
              {
                "id": 142765422,
                "url": "https://finnhub.io/api/news?id=631b204a897242e9067909ca94cf040449d481cd1c86236d331f3a110e4b093d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Vaccine and biotechnology names are leading a sharp sector rally, and a small protein-vaccine developer is posting the biggest gain of the group. Novavax (NASDAQ:NVAX) shares recently changed hands at $12.77, up 16%. Also rallying, Moderna (NASDAQ:MRNA) shares are at $219.30, up 11%, a double-digit gain that still trails Novavax stock. Meanwhile, Merck (NYSE:MRK) shares […]",
                "category": "company",
                "datetime": 1791568782,
                "headline": "Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies"
              },
              {
                "id": 142765272,
                "url": "https://finnhub.io/api/news?id=bbe1f2ebcbdec19b2d3d7a9225e75ca95b9ff0d43fd56d4c93f423c792c747fa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Healthcare stocks rose Friday afternoon, with the NYSE Healthcare Index up 1.2% and the State Street",
                "category": "company",
                "datetime": 1791568225,
                "headline": "Sector Update: Healthcare Stocks Gain Friday Afternoon"
              },
              {
                "id": 142765273,
                "url": "https://finnhub.io/api/news?id=47173bc504c3fb1af7e77e0a591d37acbd67138829b9392f495a46c5f62f2c37",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Pfizer's dividend yield has climbed well above what most blue-chip drugmakers offer, and the reason behind that gap matters far more than the number itself.",
                "category": "company",
                "datetime": 1791567949,
                "headline": "Pfizer’s Dividend Yield Is Above 6%. Wall Street May Be Sending a Warning"
              },
              {
                "id": 142764645,
                "url": "https://finnhub.io/api/news?id=017ffc0a54b8f782db50580fa23a16d185b394840ad8991564195fa4ddb45199",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index in the middle of the day on Friday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1791564011,
                "headline": "Top dow jones movers in Friday's session"
              },
              {
                "id": 142767147,
                "url": "https://finnhub.io/api/news?id=26ef6d462271e20560d857d34bb2b7d1b91d3c0bed8b86406e36dfb355f69c39",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna stock popped 9% on Friday after the New York Times reported new details about an effort to speed up cancer vaccine development. Investors saw the mRNA biotech company, in particular, as a beneficiary.",
                "category": "company",
                "datetime": 1791562498,
                "headline": "Moderna stock hits 4-year high on planned national cancer vaccine effort"
              },
              {
                "id": 142765274,
                "url": "https://finnhub.io/api/news?id=b511a432760eaf585dcbace8a10945d149a4dcfeb9e406c5b84325a24f8870a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna stock popped 9% on Friday after the New York Times reported new details about an effort to speed up cancer vaccine development. Investors saw the mRNA biotech company, in particular, as a beneficiary.",
                "category": "company",
                "datetime": 1791562498,
                "headline": "Moderna stock jumps on planned national cancer vaccine effort"
              },
              {
                "id": 142791501,
                "url": "https://finnhub.io/api/news?id=10b61961f7807912d26796789297a2d0c536581d343ea6718415855d204068b8",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/09/Two-Vials-Of-The-Moderna-Vaccine-With-A-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "A new NIH-backed initiative to speed up personalized cancer vaccine development sent stocks like MRNA, BNTX, and NVAX surging Friday.",
                "category": "company",
                "datetime": 1791558672,
                "headline": "A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally"
              },
              {
                "id": 142761581,
                "url": "https://finnhub.io/api/news?id=dac28b3748f2eb337bdde00dc47ba0bedd5c6eea64bc1a19104fa1438a7bf8c4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Cantor Fitzgerald just bumped price targets on Eli Lilly, AbbVie, Merck, and Pfizer, but higher targets do not mean equal conviction. The firm's split between Overweight and Neutral ratings reveals a sharp divide in where analysts see real upside and where near-term catalysts could disappoint.",
                "category": "company",
                "datetime": 1791547208,
                "headline": "Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants Amid Mixed Growth Outlooks"
              },
              {
                "id": 142738442,
                "url": "https://finnhub.io/api/news?id=f75e26b0729c5bff9494c60706fdff46e2e8753e7576109a0837be7c38c177d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Pfizer (PFE) stock has returned 17.5% over the past three months, easily outpacing the 3.7% return for the S&P 500. The board also just declared its 352nd quarterly dividend in a row. That reliable payout may be why many investors hold the shares, yet on Pfizer's latest earnings call, management was asked what it would take to cut that dividend. So what is Pfizer's management preparing for.",
                "category": "company",
                "datetime": 1791506167,
                "headline": "Should You Be Worried About Pfizer Stock?"
              },
              {
                "id": 142736104,
                "url": "https://finnhub.io/api/news?id=bff74f60d6f2160c55eb02e7e452a8c1637af7ee73d80472a98ad1b017bcc0e4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Regeneron Pharmaceuticals (REGN) stock currently trades at 17.6 times earnings. That represents a notable discount to the 21.5 multiple of the median S&P 500 company. The shares have lost 4.1% over the past six months, trailing the 15.7% return of the broader index. Over twelve months, however, the stock returned 27% against the index's 17.1%. A valuation this low suggests investors are either overlooking a sound drug maker or pricing in underlying problems. So how healthy is the business you wo",
                "category": "company",
                "datetime": 1791505165,
                "headline": "What Is Going On With Regeneron Stock?"
              },
              {
                "id": 142731043,
                "url": "https://finnhub.io/api/news?id=11cacb2ad0ebaf6fb9551c5ff0f0668ed0a390f9c1060697ee6f5f8ab04d468b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (NYSE:MRK) reported FDA approval of WELIREG plus LENVIMA for adults with advanced renal cell carcinoma after prior PD-1/PD-L1 therapy. The approved combination involves WELIREG at 120 mg taken once daily together with once daily LENVIMA at 20 mg. Merck also began a first-in-human Phase I trial using Cyprumed’s oral peptide delivery platform for an undisclosed peptide candidate. The WELIREG plus LENVIMA approval and Cyprumed Phase I trial are key product and pipeline moves to weigh...",
                "category": "company",
                "datetime": 1791479530,
                "headline": "Merck (MRK) Wins FDA Approval For WELIREG Plus LENVIMA In Kidney Cancer"
              },
              {
                "id": 142731004,
                "url": "https://finnhub.io/api/news?id=e801c78fc167d1485bdcb012d8e2dacd04a871eba7ae0a9dad4d30a614e313d4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Halozyme wins a Dutch court order blocking Merck's Keytruda SC in eight European markets, strengthening its position in the patent dispute.",
                "category": "company",
                "datetime": 1791474360,
                "headline": "HALO Wins Court Order Blocking Merck's Keytruda SC in Europe"
              },
              {
                "id": 142731006,
                "url": "https://finnhub.io/api/news?id=5a109b003ce25165ba0d4a6540c1081b50be8c1b4715914995cee70b54b60850",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "PFE's oncology growth in Q3 hinges on key drug sales, biosimilars and progress across a late-stage pipeline.",
                "category": "company",
                "datetime": 1791471960,
                "headline": "Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 Results"
              },
              {
                "id": 142729844,
                "url": "https://finnhub.io/api/news?id=0938183b592c662b093965ff3869dd56bb522aa6a490dfdbae4927ef8b779f1a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "INVA vs. MRK: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1791470403,
                "headline": "INVA vs. MRK: Which Stock Is the Better Value Option?"
              },
              {
                "id": 142727185,
                "url": "https://finnhub.io/api/news?id=af927b0037b94c74ca80fab6b0dc7f209a30bc876880f655f7ec6f6a5a778891",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The firm said Pfizer’s near-term performance largely depends on results from the Mevpro-1 trial of Mevrometostat, an experimental prostate cancer drug.",
                "category": "company",
                "datetime": 1791466552,
                "headline": "PFE, LLY, MRK Stocks In Focus: Cantor Raises Price Targets On Pharma Behemoths, But Flags Growth Concerns For Pfizer"
              },
              {
                "id": 142727204,
                "url": "https://finnhub.io/api/news?id=0777919541fde067a3ae7f2057a4e37174b1a46ec3889aa06a812dc2cfa4d84e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Amgen (AMGN) stock has returned 44% over the past twelve months, easily outpacing the 17.1% gain for the S&P 500. Investors looking at that rally might question what catalysts remain to push shares higher. One candidate is an experimental therapy that is not yet on the market, and executives say its development is progressing rapidly. So what is that drug, and how far along is it.",
                "category": "company",
                "datetime": 1791464604,
                "headline": "What Would It Take For Amgen Stock To Move Higher?"
              },
              {
                "id": 142727205,
                "url": "https://finnhub.io/api/news?id=b9f422449f20b422638b049720516a8121f59c7b4b7cec48f8a6697c9914b67e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck is the most exposed to risk from generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and others will also grapple with patent losses in the years to come.",
                "category": "company",
                "datetime": 1791464400,
                "headline": "Pharma’s $500B patent problem will come in waves — not as a cliff"
              },
              {
                "id": 142727249,
                "url": "https://finnhub.io/api/news?id=f1f16c634cdaf1264e52627dfa0f5d8fa07dbdbf74cb507775f98e87795a9933",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "On October 7, three companies with nothing in common sent cash to their shareholders, but the differences in what each paid, how fast each raised it, and what the stock price does to the math tell three very different income stories.",
                "category": "company",
                "datetime": 1791462006,
                "headline": "HP, Merck, and Seagate Just Paid Their Shareholders. Here’s What Landed in Their Accounts."
              },
              {
                "id": 142727251,
                "url": "https://finnhub.io/api/news?id=f7b2dc60e7944c418a54200a105d62bafcdc6bf6b92eaf8327925bd73a4ef4cf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "MRNA's Nasdaq-100 entry follows a 566% stock surge and stronger cancer therapy prospects, potentially boosting demand from index-tracking funds.",
                "category": "company",
                "datetime": 1791459720,
                "headline": "Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock?"
              },
              {
                "id": 142725284,
                "url": "https://finnhub.io/api/news?id=27135e9e07b38f712fa76d28aca7aafd38bbc9d427ad47bc19efe577d51ea1a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Three stocks left the S&P 500's 2025 return in the dust, but gains that large raise one uncomfortable question: is the opportunity already gone, or does one of them still have a real runway ahead?",
                "category": "company",
                "datetime": 1791459058,
                "headline": "3 Stocks That Have More Than Doubled the S&P 500’s Return This Year"
              },
              {
                "id": 142761278,
                "url": "https://finnhub.io/api/news?id=7ba3ed272714de30d8449468da93c18b22f4812734ad8a9471a40b76efa0b11b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/08/Stock-Market-Trading-Chart-And-Analyzing.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Three sectors are higher and eight are lower in Thursday's regular session, with the top three split across cyclical, defensive and growth groups. The leaders are separated rather than clustered, with Energy clearly ahead of the next sectors in the ranking.",
                "category": "company",
                "datetime": 1791457745,
                "headline": "8 Of 11 Sectors Fall In Thursday Trading As Energy Leads"
              },
              {
                "id": 142727189,
                "url": "https://finnhub.io/api/news?id=760fce1518bbb39e0b14474dc1ed7232e38a2ceb9a2cd815abd69688e7ac31b5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "LLY's oncology portfolio is poised for growth as Jaypirca, Inluriyo and Retevmo may offset slower Verzenio sales and mature-drug declines.",
                "category": "company",
                "datetime": 1791457500,
                "headline": "How Is Eli Lilly's Oncology Portfolio Poised Ahead of Q3 Earnings?"
              },
              {
                "id": 142721987,
                "url": "https://finnhub.io/api/news?id=02de64a2433e5ae4d52559717f216110ad55a62d138ef1a4d5b1276a99088b55",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Up from about US$300 million in 2025 across the US, EU4, UK and Japan, as Merck's WELIREG, the first oral targeted PCPG therapy, faces pipeline rivals from Novartis, Jazz and Perspective.Dublin, Oct. 08, 2026 (GLOBE NEWSWIRE) -- \"Pheochromocytomas and Paragangliomas (PCPG) - Market Insights, Epidemiology, and Market Forecast - 2036\" has been added to ResearchAndMarkets.com's offering. Pheochromocytoma and Paraganglioma (PCPG) Market Insights, Epidemiology and Forecast to 2036 Pheochromocytoma an",
                "category": "company",
                "datetime": 1791455400,
                "headline": "Pheochromocytoma and Paraganglioma (PCPG) Market to Reach US$670 Million by 2036 at 7.3% CAGR, Driven by Targeted and Radioligand Therapies"
              },
              {
                "id": 142716558,
                "url": "https://finnhub.io/api/news?id=00a1273c3f399fc738a591a7a6ddbf203fa1358f6259301261b4569da6f9d1d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "135-Page Report Tracks Bayer and Merck's ADEMPAS (Riociguat) as the Leading Therapy as Combination Regimens and Balloon Pulmonary Angioplasty Reshape CTEPH TreatmentDublin, Oct. 08, 2026 (GLOBE NEWSWIRE) -- \"Chronic Pulmonary Hypertension - Market Insights, Epidemiology, and Market Forecast - 2036\" has been added to ResearchAndMarkets.com's offering. The Chronic Pulmonary Hypertension (CPH) - Market Insights, Epidemiology and Market Forecast - 2036 report provides a comprehensive assessment of t",
                "category": "company",
                "datetime": 1791447420,
                "headline": "Chronic Pulmonary Hypertension Market Insights, Epidemiology, and Market Forecast - 2036 Report Reveals Why a Limited Pipeline Leaves the 7MM Market Without a Curative Leader"
              },
              {
                "id": 142717891,
                "url": "https://finnhub.io/api/news?id=040bc921f0873aed756d0699390f406b17239c55d2749f24093c4bc74c32e4a6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Halozyme’s argenx expansion puts ENHANZE back in focus Halozyme Therapeutics (HALO) extended its ENHANZE collaboration with argenx to cover two more exclusive targets, taking the total to eight and adding fresh attention to the stock’s partnership-driven revenue model. Under the expanded agreement, Halozyme is eligible for milestone payments linked to development and commercial progress, as well as royalties on net sales of ENHANZE based products. This keeps investor focus on execution rather...",
                "category": "company",
                "datetime": 1791447247,
                "headline": "Halozyme Therapeutics (HALO) Expands Argenx Deal, Is It Still 27% Below Fair Value?"
              },
              {
                "id": 142728864,
                "url": "https://finnhub.io/api/news?id=aa9b74fc8cf0bd33346f1b03ffb5f89252bc4f13518a08033d2c90ce931545ec",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Cantor Fitzgerald  analyst Carter Gould   maintains Merck & Co (NYSE:MRK) with a Neutral and raises the price target from $120 to $145.",
                "category": "company",
                "datetime": 1791441877,
                "headline": "Cantor Fitzgerald Maintains Neutral on Merck & Co, Raises Price Target to $145"
              },
              {
                "id": 142727055,
                "url": "https://finnhub.io/api/news?id=58bccab68fc54cae0b3b7fee41a3bfdbe01117018ca16d59a9a039d148c60a9a",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "https://www.bloomberg.com/news/articles/2026-10-08/russia-denies-report-of-second-case-of-illness-in-siberia",
                "category": "company",
                "datetime": 1791439197,
                "headline": "'Russia Denies Report of Second Case of Illness in Siberia' - Bloomberg"
              },
              {
                "id": 142701310,
                "url": "https://finnhub.io/api/news?id=be0a7e3fa760ed5f0a5c52227739c617a8ce6b41a96fbf2c446e8d620797eaa5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Exelixis (EXEL) stock has returned 46% over the past twelve months, compared with 17.8% for the S&P 500. The company has aggressively repurchased its own stock, reducing its total share count by 21% over the last three years. Because fewer shares remain in circulation, each one lays claim to a larger slice of the profit. So how much is that buyback adding to each Exelixis share you own.",
                "category": "company",
                "datetime": 1791414880,
                "headline": "Is Exelixis Stock Engineered To Make You Money?"
              },
              {
                "id": 142700367,
                "url": "https://finnhub.io/api/news?id=e41779b14869ae7ee1130d642ae0798afcbd5d5b9cbe7592ea3267727b02ac2c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "In late September 2026, a Dutch court ruled in favor of Halozyme Therapeutics, issuing an injunction that halts manufacture and sale of Merck’s subcutaneous Keytruda in eight European countries following a patent dispute. This setback affects one of Merck’s key immuno-oncology formulations in important European markets, highlighting how legal outcomes can directly influence product access and portfolio planning. We’ll now examine how this injunction affecting subcutaneous Keytruda in several...",
                "category": "company",
                "datetime": 1791407592,
                "headline": "Is Halozyme’s EU Injunction on Subcutaneous Keytruda Reshaping the Investment Case For Merck (MRK)?"
              },
              {
                "id": 142729845,
                "url": "https://finnhub.io/api/news?id=c014997ea957db0fc1fb6fa694849438778cb31eac31201357a3ff84d06878f2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Tempus, a medical testing and healthcare tech company, has partnered with industry giants like Merck and Moderna to revolutionize healthcare. Founder and chief executive Eric Lefkofsky discusses these partnerships, Tempus's financial strategy and the success and failures of AI in healthcare.",
                "category": "company",
                "datetime": 1791407580,
                "headline": "Tempus CEO on How AI Can Save Healthcare"
              },
              {
                "id": 142699343,
                "url": "https://finnhub.io/api/news?id=dfdf650e7cc8a91fd88dd02eee89a616b47dc77c4fa2c5a8d102e1f604903f92",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index adding 1.2% and the",
                "category": "company",
                "datetime": 1791402441,
                "headline": "Sector Update: Healthcare Stocks Rise Late Afternoon"
              },
              {
                "id": 142699052,
                "url": "https://finnhub.io/api/news?id=79cbbb6a9394d74f43ed5875e5d2b638c156a24824ea95997addfce18685ce40",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Stay updated with the movements of the dow jones index one hour before the close of the markets on Wednesday. Discover which stocks are leading as top gainers and losers in today's session.",
                "category": "company",
                "datetime": 1791400214,
                "headline": "Top dow jones movers in Wednesday's session"
              },
              {
                "id": 142698348,
                "url": "https://finnhub.io/api/news?id=0488066b399180d0528892e018d49d01525df360795c8bbcfccdd7cdf3f2d269",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 1.6% and the State",
                "category": "company",
                "datetime": 1791395201,
                "headline": "Sector Update: Healthcare Stocks Rise in Afternoon Trading"
              },
              {
                "id": 142699368,
                "url": "https://finnhub.io/api/news?id=844580da2d37328ae230aab32ca06289ade7fbdcd838d97dc779f53af701318d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Reblozyl's strong growth is helping Bristol Myers offset declining legacy drug sales, with new indications offering further upside.",
                "category": "company",
                "datetime": 1791394200,
                "headline": "Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?"
              },
              {
                "id": 142697832,
                "url": "https://finnhub.io/api/news?id=7035659f7d8a2a0d5730ed16bd3bcb7683148f81f5fe35ce66fb9682da838018",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Wondering what's happening in today's session for the dow jones index? Stay informed with the top movers within the dow jones index on Wednesday.",
                "category": "company",
                "datetime": 1791391212,
                "headline": "Which dow jones stocks are moving on Wednesday?"
              },
              {
                "id": 142698430,
                "url": "https://finnhub.io/api/news?id=68fc56f4ac741382e516c4c861aaebe40253a079a2901ed7ef0acfa7231383f2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "A Dutch court rules in favor of Halozyme Therapeutics, barring Merck from selling subcutaneous Keytruda in eight European markets.",
                "category": "company",
                "datetime": 1791390000,
                "headline": "Merck’s Keytruda Is Dealt a Legal Setback. It’s Good News for This Biotech Stock."
              },
              {
                "id": 142698403,
                "url": "https://finnhub.io/api/news?id=24cab9c3b44d655fea5e81162fe16de373b29b91fba1401c2a64dc187a69aaff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Eli Lilly (LLY) stock is priced at 38.7 times earnings, compared with 21.5 for the S&P 500. Investors evaluating that valuation should weigh what drives it, especially since the company's priorities have shifted. In late 2024, management opened its earnings call by detailing how many doses of its weight-loss and diabetes drugs it could manufacture. Today, the primary focus has broadened considerably beyond factory output. So what is it.",
                "category": "company",
                "datetime": 1791389636,
                "headline": "Why You Should Think About Eli Lilly Stock Differently Now"
              },
              {
                "id": 142697130,
                "url": "https://finnhub.io/api/news?id=ab9e1c9545f2c8c9e2102b5fe6f35b4bd882d5df28e3eb0153a6eb168e2513c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Investing.com --Halozyme Therapeutics Inc (NASDAQ:HALO) shares rose 2% Wednesday after the company won a patent infringement injunction against Merck's Keytruda SC in multiple European markets.",
                "category": "company",
                "datetime": 1791386514,
                "headline": "Halozyme stock rises after winning injunction against Merck"
              },
              {
                "id": 142697131,
                "url": "https://finnhub.io/api/news?id=ae1226bd9094f32438cd7331bcb6012f816a512141a53bdc5f6cebc33fd261be",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "A Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ended a seven-year run and two startups secured venture cash.",
                "category": "company",
                "datetime": 1791386460,
                "headline": "Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial"
              },
              {
                "id": 142727689,
                "url": "https://finnhub.io/api/news?id=111a5acaac46f167d1961c88b8fc1c3249af2292e699a5d3873804e67dbd074c",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/07/Tempus-AI-Logo-On-Mobile-Phone.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Tempus AI expands its collaboration with Moderna and Merck to support sample collection and NGS services for intismeran autogene and Keytruda.",
                "category": "company",
                "datetime": 1791380692,
                "headline": "Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure"
              },
              {
                "id": 142694830,
                "url": "https://finnhub.io/api/news?id=a910c3cf1307093aa71a865be7653c98d311d7479d788b9de6f7506bfabb510d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "CHICAGO, October 07, 2026--Tempus (NASDAQ: TEM) today announced an expanded, multi-year collaboration to support the potential commercialization of intismeran autogene (V940/mRNA-4157), a novel, potential first-in-class individualized neoantigen therapy (INT) being evaluated in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with completely resected stage IIB-IV melanoma and other cancer types. Intismeran autogene is jointly developed by Moderna and Merck, know",
                "category": "company",
                "datetime": 1791376200,
                "headline": "Tempus Announces Multi-Year Collaboration with Moderna and Merck"
              },
              {
                "id": 142696865,
                "url": "https://finnhub.io/api/news?id=f5cc9877b0d6b56d9f45c7b5926b6c81bc5d7a245f22a4efe3e081f0f0ea3d56",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1749214597/image_1749214597.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "October 2026 finds 21 of 30 Dow stocks with sufficient free cash flow to support dividends, but none are ideally fair-priced by yield standards.",
                "category": "company",
                "datetime": 1791372708,
                "headline": "October Dogs Of The Dow: No Buys But 10 Are Worth Watching"
              },
              {
                "id": 142728867,
                "url": "https://finnhub.io/api/news?id=de58f239415cafa3580a4e34db7c89109fd42f647f0370d1c2dc5e2da65ee495",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Morgan Stanley  analyst Terence Flynn   maintains Merck & Co (NYSE:MRK) with a Overweight and lowers the price target from $179 to $177.",
                "category": "company",
                "datetime": 1791370250,
                "headline": "Morgan Stanley Maintains Overweight on Merck & Co, Lowers Price Target to $177"
              },
              {
                "id": 140021632,
                "url": "https://finnhub.io/api/news?id=d59fa2d57f5d72ceaf715456b9c437259fca597bd6c28276fb57903ea3c319c9",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "",
                "category": "company",
                "datetime": 1791362292,
                "headline": "Halozyme Therapeutics shares are trading lower after the company reported mixed Q4 financial results."
              },
              {
                "id": 142668744,
                "url": "https://finnhub.io/api/news?id=573ef61ba9a2a446cd6428790fd5bde78497050a141c024bcd102c514cec5e0c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) reached $141.94 at the closing of the latest trading day, reflecting a +1.72% change compared to its last close.",
                "category": "company",
                "datetime": 1791319804,
                "headline": "Merck (MRK) Beats Stock Market Upswing: What Investors Need to Know"
              },
              {
                "id": 142667426,
                "url": "https://finnhub.io/api/news?id=d746261ff29e9cc44ef27036fcaea7bc30f5ad242ea1e6c22ec443fb552f4afd",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Curious about the top performers within the dow jones index one hour before the close of the markets on Tuesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.",
                "category": "company",
                "datetime": 1791313811,
                "headline": "Stay informed with the top movers within the dow jones index on Tuesday."
              },
              {
                "id": 142667904,
                "url": "https://finnhub.io/api/news?id=a83aaea651b657c3ecdf60984e7097e9cc1703beaa77b846356c44ef1006fa0f",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2298029859/image_2298029859.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Vaxcyte stays a Strong Buy after VAX-31 phase 3 OPUS-1 success; broader pneumococcal coverage and 2027 catalysts are ahead. Click for more on PCVX.",
                "category": "company",
                "datetime": 1791302684,
                "headline": "Vaxcyte: 'Strong Buy' On VAX-31 Trial Win IPD VAX-31 And Additional Readouts 1st Half 2027"
              },
              {
                "id": 142665591,
                "url": "https://finnhub.io/api/news?id=4fe7eff21e7fc3ab280e5978693cc4f9850e9ea6400a8bab1ab7d9c4e8677d7f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Biotech stocks took a hit Tuesday, with Vaxcyte, Moderna and Revolution Medicines posting some of the steepest losses.",
                "category": "company",
                "datetime": 1791301145,
                "headline": "Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest Losers"
              },
              {
                "id": 142665590,
                "url": "https://finnhub.io/api/news?id=b8c24771ec9f2acfa0c2c2695e7d6df91fc9d0d11a2219c92c917dfea329fe3a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck's 7% dip may offer a buying opportunity as Keytruda drives growth and new products and pipeline assets strengthen its post-2028 outlook.",
                "category": "company",
                "datetime": 1791297120,
                "headline": "Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity?"
              },
              {
                "id": 142662987,
                "url": "https://finnhub.io/api/news?id=bac971396bdc677b3a7769ad8cff18fad8e03f7b75d5f59895750484d0ce7dee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "VAX-31 matched or beat Pfizer's Prevnar 20 and Merck's Capvaxive on nearly all measured strains in the OPUS-1 trial",
                "category": "company",
                "datetime": 1791290648,
                "headline": "Vaxcyte VAX-31 pneumococcal vaccine phase 3 trial results"
              },
              {
                "id": 142662034,
                "url": "https://finnhub.io/api/news?id=92baf4e01a6cc114e359c1d9568a4ba6e164aca65b04b08f10ddcb0fb16f8b8f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.",
                "category": "company",
                "datetime": 1791283234,
                "headline": "2 Unpopular Stocks That Should Get More Attention and 1 Facing Challenges"
              },
              {
                "id": 142662035,
                "url": "https://finnhub.io/api/news?id=9481b46988e42ac53af13e068b860e18bbfb1c342506a34519b2a1e37d19ba47",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Key TakeawaysVaxcyte’s VAX-31 matched Pfizer’s Prevnar 20 on all 20 shared serotypes and Merck’s Capvaxive on 17 of 19 in a 4,047-person Phase 3 trial. Prevnar brought in $6.",
                "category": "company",
                "datetime": 1791265085,
                "headline": "Pfizer’s $6.49 Billion Prevnar Franchise Faces a New Challenger"
              },
              {
                "id": 142662717,
                "url": "https://finnhub.io/api/news?id=0af991e44b8c081ec4bcc3537f414b1df1de5d750dfde4af55ad85a15eb03f4c",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/06/Combination-Products-Face-Scrutiny.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Vaccine stocks are trending on Tuesday.\n\n\n\nShares of Moderna Inc. (NASDAQ:MRNA), Vaxcyte Inc. (NASDAQ:PCVX) and Novavax Inc. (NASDAQ:NVAX) are moving in the after-hours session on Monday.\n\n\n\nModerna rose 0.17% to",
                "category": "company",
                "datetime": 1791246461,
                "headline": "Moderna, Vaxcyte and Novavax Are Trending After-Hours as Suspected Pneumonic Plague In Russia Stirs Anxiety"
              },
              {
                "id": 142639127,
                "url": "https://finnhub.io/api/news?id=093d90fe4555587549afe71efd25ecc69c702f24e351eb673b6eb571c324d0ac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The Dow Jones index rises Monday. Brazil stocks soar on election results, with some clearing entries. SpaceX shines on the stock market today.",
                "category": "company",
                "datetime": 1791233315,
                "headline": "Stock Market Today: Dow Gains, Nasdaq Hits New High; Shopify, Brazil Plays Offer Entries"
              },
              {
                "id": 142638487,
                "url": "https://finnhub.io/api/news?id=85fbe6e259994956d206666ce9bd76965db090724695c13359d2045247dc66f8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Nasdaq said on October 1 that Moderna will join the Nasdaq-100 before the open on October 9, replacing Warner Bros. Discovery.",
                "category": "company",
                "datetime": 1791228622,
                "headline": "MRNA Stock Soars Ahead Of Slated Return To Nasdaq-100; Retail Echoes Valuation Concerns"
              },
              {
                "id": 142638289,
                "url": "https://finnhub.io/api/news?id=0e88a10f0ad90454a5ff9c1b9d8c6be70f11a0beeaf98797fe4fc38372abaa20",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Stay informed about the performance of the dow jones index one hour before the close of the markets on Monday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1791227409,
                "headline": "Monday's session: top gainers and losers in the dow jones index"
              },
              {
                "id": 142638288,
                "url": "https://finnhub.io/api/news?id=4796f000e83db0803c6b2ad30c002a2fc93fd2d01cc72622994706b14f78ea94",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Monday.",
                "category": "company",
                "datetime": 1791227101,
                "headline": "Uncover the latest developments among S&P500 stocks in today's session."
              },
              {
                "id": 142638473,
                "url": "https://finnhub.io/api/news?id=a0aed603f70bc8ef264d79f324d24d5701ee850ef739f8229b152e269fcdd855",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Key TakeawaysAbbVie yields 2. 7% and Merck 2.",
                "category": "company",
                "datetime": 1791227027,
                "headline": "Better Dividend for Retirees: AbbVie vs. Merck"
              },
              {
                "id": 142638488,
                "url": "https://finnhub.io/api/news?id=b912328faf2b062f4a6208a16967cb22fa7e13d4e2d406d3f1a441f06bfdc313",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna stock has surged nearly 600% this year on a cancer vaccine trial result that almost no one outside the trial has actually seen in full. What happens when Madrid finally puts the complete data in front of the market?",
                "category": "company",
                "datetime": 1791226022,
                "headline": "Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips"
              },
              {
                "id": 142638489,
                "url": "https://finnhub.io/api/news?id=75b0bd8242f594950d0b5981d4cc6a0d4cecf283f71ac005bb853e91883c8c2d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "In the OPUS-1 study, Vaxcyte’s VAX-31 matched or beat immune responses from Pfizer’s Prevnar 20 and Merck’s Capvaxive on most strains those vaccines cover.",
                "category": "company",
                "datetime": 1791225445,
                "headline": "PCVX Stock Hits Fresh 52-Week High On Late-Stage Win In Adult Pneumonia Vaccine Race: Jefferies Says It Hit ‘Blue-Sky’ Case"
              },
              {
                "id": 142666439,
                "url": "https://finnhub.io/api/news?id=1a5c6c94f3c93fa001ef048cd1a77a01f6d7b55e5fd4087cab86b5a080486288",
                "image": "https://image.cnbcfm.com/api/v1/image/108372913-17912377341791237730-48813583934-1080pnbcnews.jpg?v=1791237733&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "John Flavin, Portal Innovations founder and CEO, joins 'Fast Money' to talk the state of the pharma trade.",
                "category": "company",
                "datetime": 1791223895,
                "headline": "Pharma is an impatient market, says Portal's John Flavin on Novo's struggles"
              },
              {
                "id": 142637663,
                "url": "https://finnhub.io/api/news?id=9cb40806a1edccc2be135ed333e8a8f34bac9588a9f2e93874bf96ad7b0c0645",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The Dow Jones index rises Monday. Brazil stocks soar on election results. Microsoft and SpaceX shine on the stock market today.",
                "category": "company",
                "datetime": 1791223003,
                "headline": "Stock Market Today: Dow Up As Microsoft, SpaceX Pop; Brazil Play, Chip Leader Offer Entries (Live Coverage)"
              },
              {
                "id": 142637796,
                "url": "https://finnhub.io/api/news?id=fc9b3abfa01aa678c25ac5c60cc919be0aa63ebcd06a46aa465cd2f98dd414bb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the latest trial results, Jefferies says.",
                "category": "company",
                "datetime": 1791219120,
                "headline": "Vaxcyte Stock Spikes 27% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck"
              },
              {
                "id": 142637485,
                "url": "https://finnhub.io/api/news?id=67961b010b1f3caecc8f221b133dc532a01b4d12e570aa9d8e37f37167ccb5a0",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Monday.",
                "category": "company",
                "datetime": 1791218101,
                "headline": "Which S&P500 stocks are moving on Monday?"
              },
              {
                "id": 142636687,
                "url": "https://finnhub.io/api/news?id=b410b51db0836c85174f444e29e0b734d619a2271eaff50cea07bc12d56c6c7a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The Dow Jones index falls Monday but other indexes rally. Nvidia stock clears a buy point. Microsoft and SpaceX shine.",
                "category": "company",
                "datetime": 1791213490,
                "headline": "Stock Market Today: Dow Dips As Services Data Shows This; Microsoft, SpaceX Pop (Live Coverage)"
              },
              {
                "id": 142636830,
                "url": "https://finnhub.io/api/news?id=fe851ebbde9421b13e2c41dca244f8ddd15ae8509f691c4bfbc273aa263ab46e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the latest trial results, Jefferies says.",
                "category": "company",
                "datetime": 1791212940,
                "headline": "Vaxcyte Stock Spikes 35% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck"
              },
              {
                "id": 142636832,
                "url": "https://finnhub.io/api/news?id=8592b72576cd9ebfb95b9b83b8a78982189859bf0b0ccae1adf2364ecea3841d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Precigen is building momentum with Papzimeos sales growth, a European regulatory review and progress across its AdenoVerse pipeline.",
                "category": "company",
                "datetime": 1791211440,
                "headline": "PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know"
              },
              {
                "id": 142636833,
                "url": "https://finnhub.io/api/news?id=04ad7948488d41cdc49895e8fe1dac9a9b0585519ec95bcc6771a222157bb5ad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Key TakeawaysVaxcyte shares are up about 36% after its VAX-31 pneumococcal vaccine met every primary goal in OPUS-1, its pivotal adult Phase 3 trial. VAX-31 cleared a stricter-than-usual bar against Pfizer’s Prevnar 20 on all 20 shared strains, but on only 17 of 19 against Merck’s Capvaxive.",
                "category": "company",
                "datetime": 1791211396,
                "headline": "Vaxcyte Soars 36% on Phase 3 Pneumococcal Vaccine Win That “Sets a New Benchmark”"
              },
              {
                "id": 142636834,
                "url": "https://finnhub.io/api/news?id=d9cdb4ebfa46d35515eaf043f5ff52014a8cfaf52f65b85f5469c2f7de74a21d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Vaxcyte’s vaccine was pitted against standard-of-care jabs and proved non-inferior on nearly all serotypes.",
                "category": "company",
                "datetime": 1791211159,
                "headline": "Vaxcyte’s stock up after pneumococcal vaccine proves non-inferiority"
              },
              {
                "id": 142636258,
                "url": "https://finnhub.io/api/news?id=29efb9272e34194989ca6cbc84d29c5a3f9fe9d98e4e151f9a926c3e72b44583",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Wondering which stocks are making significant price gaps? Explore the S&P500 index on Monday to find the gap up and gap down stocks in today's session.",
                "category": "company",
                "datetime": 1791210902,
                "headline": "These S&P500 stocks are gapping in today's session"
              },
              {
                "id": 142636835,
                "url": "https://finnhub.io/api/news?id=b69847d67de97721bb469c835a3eb53af7c7d84086b6e2d012983d6e64c7084d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Vaxcyte (NASDAQ:PCVX) shares surged 57% in morning trading on Monday after the biotechnology company said its experimental pneumococcal vaccine VAX-31 generated immune responses comparable to rival vaccines in a late-stage study. The results strengthened expectations that VAX-31 could compete...",
                "category": "company",
                "datetime": 1791210720,
                "headline": "Vaxcyte shares surge on late-stage vaccine trial success"
              },
              {
                "id": 142636798,
                "url": "https://finnhub.io/api/news?id=02b55fb819eac16ad9dadcdcb5f78fd4425f22a5be3f5f3a3aaf11e2f425c375",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "One thing stands out at Eli Lilly (LLY): how many prescriptions are written for Zepbound and Mounjaro, which may be what buyers are betting on. You may think of them as high-priced drugs, but their U.S. prices are now falling. Yet the stock costs 38.2 times earnings, against 21.5 for the S&P 500. That is the tension. So, how much are the two drugs actually selling.",
                "category": "company",
                "datetime": 1791209955,
                "headline": "Has Eli Lilly Stock Peaked?"
              },
              {
                "id": 142636837,
                "url": "https://finnhub.io/api/news?id=fd962f68cae7aa4078ea11a3895e70baf7df37b780aaa3d2254b9a5560db3c32",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The company’s next-generation shot surpassed Wall Street’s expectations by matching the effectiveness of vaccines from Pfizer and Merck on nearly all bacterial strains in the first of three Phase 3 trials.",
                "category": "company",
                "datetime": 1791208320,
                "headline": "Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data"
              },
              {
                "id": 142635079,
                "url": "https://finnhub.io/api/news?id=bbd50232421bb8e0197a66b8016f056af60d001a7acb4adc7d6032521fe23ae1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Vaxcyte stock catapulted Monday after its experimental pneumococcal vaccine proved it's not inferior to marketed shots from Pfizer and Merck.",
                "category": "company",
                "datetime": 1791206339,
                "headline": "Vaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine Study"
              },
              {
                "id": 142636838,
                "url": "https://finnhub.io/api/news?id=44addfb1c4d5eaf25856435029be8695557069d46edca7716c2b738b88372302",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Vaxcyte Inc. (NASDAQ:PCVX) stock is surging on Monday on positive topline results from its pivotal Phase 3 OPUS-1 trial evaluating VAX-31, an investigational 31-valent pneumococcal conjugate vaccine.The trial assessed the safety, tolerability, and immunogenicity of the candidate in adults to prevent invasive pneumococcal disease and pneumococcal pneumonia.These trial findings will form the foundation for an upcoming Biologics License Application submission to the U.S. Food and Drug Administratio",
                "category": "company",
                "datetime": 1791204917,
                "headline": "Vaxcyte Stock Hits New 52-Week High - Here’s Why"
              },
              {
                "id": 142663898,
                "url": "https://finnhub.io/api/news?id=7e61d0fd607de5a67edddeacb41623a94f4d6a57ce2e19a728987f2558b4c8cb",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "JP Morgan  analyst Chris Schott   maintains Merck & Co (NYSE:MRK) with a Overweight and raises the price target from $150 to $165.",
                "category": "company",
                "datetime": 1791201652,
                "headline": "JP Morgan Maintains Overweight on Merck & Co, Raises Price Target to $165"
              },
              {
                "id": 142635080,
                "url": "https://finnhub.io/api/news?id=913bb3e910c137bda22384e931cac1d2292fb0d6c994723cf17e33d7d77c44be",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "(OTC PINK:VICP) (\"VICP\" or the \"Company\") today announced that FutureBrand, the global brand consultancy behind the corporate identities of Sanofi, GSK and Merck, has onboarded the Company as a client through its Latin America practice and delivered a new corporate identity for Vicapsys Life Sciences and its wholly owned subsidiary, of Puerto Rico, Inc. The rollout of the new identity is the first in a series of corporate housekeeping steps the Company is completing following its reverse merger",
                "category": "company",
                "datetime": 1791201600,
                "headline": "Housekeeping Starts with Branding: Vicapsys Life Sciences Adopts New Corporate Identity Developed by FutureBrand for Vicapsys and Its Stateline Subsidiary"
              },
              {
                "id": 142634275,
                "url": "https://finnhub.io/api/news?id=79e8a4a1c0aeae961e7785bb87893534635e3e9d7ea15bb2d19eaa65fabaa588",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Ten consecutive earnings beats and a shrinking COVID hangover have Wall Street split on whether Pfizer deserves a breakout or a ceiling, and the answer hinges on a single pipeline deal that could reshape the obesity drug race.",
                "category": "company",
                "datetime": 1791198942,
                "headline": "Pfizer’s Turnaround Could Be Bigger Than Investors Think, Set For 20% Upside"
              },
              {
                "id": 142662620,
                "url": "https://finnhub.io/api/news?id=9b99f160d0e43a3fbf1e99dbf628b2d476cc0c04d5292e521e81f816b5d747e0",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/05/Technical-analysis.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Eight sectors are higher and three are lower in Monday's regular session, with growth, cyclical and defensive sectors split across the top three positions. The leaders are separated rather than clustered.",
                "category": "company",
                "datetime": 1791198136,
                "headline": "8 Of 11 Sectors Rise In Monday Trading As Leaders Split"
              },
              {
                "id": 142633167,
                "url": "https://finnhub.io/api/news?id=adb9f2f0b1b55601aabcf44f8ff3bf2965b0e51ef0c15b28b0acef4f8ec0c105",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Dublin, Oct. 05, 2026 (GLOBE NEWSWIRE) -- \"Custom Recombinant Proteins Market - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering. The global custom recombinant proteins market was valued at US$5.3 billion in 2024 and is projected to reach US$10 billion by 2030, expanding at a compound annual growth rate (CAGR) of 11.2%. Market growth is supported by rising biopharmaceutical research and development, expanding biologics pipelines, advances in protein engineeri",
                "category": "company",
                "datetime": 1791195300,
                "headline": "Custom Recombinant Proteins Market - Global Strategic Business Report 2026 | Capture the $10 Billion 2030 Shift as Thermo Fisher Scientific, Merck, GenScript, and Sino Biological Redefine Scale"
              },
              {
                "id": 142628177,
                "url": "https://finnhub.io/api/news?id=5e559ccc13458107f69a755a0fa898e408a9fd80fe5863d30ee438f401301bbe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna Inc. (NASDAQ:MRNA) ranked as the second top-performing stock in the US market in the third quarter of the year, with the surge primarily driven by rosy growth prospects from its combined therapy candidate for treating the most common type of skin cancer. The vaccine maker—which is set to join the Nasdaq 100 index on […]",
                "category": "company",
                "datetime": 1791169645,
                "headline": "Moderna (MRNA) Soars 175% in Q3: Can The Stock Keep Running?"
              },
              {
                "id": 142625230,
                "url": "https://finnhub.io/api/news?id=1f51c558984ec226824455a50b00a46c9e2ddcacb6b7235dfdfca49a3f6fdf0e",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2266875637/image_2266875637.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Compare VFLO vs CGDV ETFs: VFLO offers better value (15.8x P/E) and AI tailwinds, while CGDV adds mega-cap dividends.",
                "category": "company",
                "datetime": 1791129794,
                "headline": "VFLO And CGDV: The Perfect Pairing For AI Growth"
              },
              {
                "id": 142623564,
                "url": "https://finnhub.io/api/news?id=0239c0fdaed29155b6cf30b792945e313c370a2fe0edfe251cd76905a7b7f109",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2270977838/image_2270977838.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "BioNTech pivots from Covid windfall to oncology with 33 trials and $19B cash; key pumitamig data post-2028. Click for more on BNTX stock.",
                "category": "company",
                "datetime": 1791107051,
                "headline": "BioNTech SE: Moving Past Covid"
              },
              {
                "id": 142616490,
                "url": "https://finnhub.io/api/news?id=d9c2344d2d2cd7c0bfb9fbfb23955a03d2c54ee9c0b0f3d9caf32c350c4a7380",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Key TakeawaysMerck stock is up 61% over the past year to $144 at the Oct 2 close, with the sharpest leg coming Aug 19 on the Phase 3 INTerpath-001 melanoma win. Scotiabank’s Sept 29 target hike to $180 from $155 sits 25% above the close.",
                "category": "company",
                "datetime": 1791052306,
                "headline": "Merck Stock Is Up 61% in a Year. Is There Room Left to Run?"
              },
              {
                "id": 142624150,
                "url": "https://finnhub.io/api/news?id=7e2cb675536c0c9b14dc0f8ac39311049b0a11e1b60c46a7ab6ab60875ed1795",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "With the 10-year Treasury yielding around 5.3%, Pfizer, Energy Transfer, and Plains All American offer stocks under $30 with dividend yields between 6% and 7%.",
                "category": "company",
                "datetime": 1791038700,
                "headline": "3 Income Stocks Under $30 That Yield More Than the 10-Year Treasury Note"
              },
              {
                "id": 142596125,
                "url": "https://finnhub.io/api/news?id=91306fa3d9deb441f4497b6d7a76a19ba222c2b00e2a72e156a56807caad6a3e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Biotech companies this week spent on experimental therapies, including autoimmune drugs, next-generation obesity pills and cancer combinations.",
                "category": "company",
                "datetime": 1790986415,
                "headline": "Stocktwits Biotech Dealmaker — Novartis, Sanofi And Novo Sign Week’s Biggest Deals"
              },
              {
                "id": 142594354,
                "url": "https://finnhub.io/api/news?id=161416d9fe0af8d5b2d7f4d9d69475fcb9166bdffb075153d025cb4aaef3b027",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (NYSE:MRK) reported positive Phase 2b results for tulisokibart in moderate to severe hidradenitis suppurativa on 1 October 2026. The investigational anti TL1A monoclonal antibody met its Phase 2b efficacy goals in patients with this chronic inflammatory skin condition. Merck stated that tulisokibart's Phase 2b data support advancing the program into Phase 3 trials in hidradenitis suppurativa. There is much more to Merck's story than the tulisokibart Phase 2b milestone in hidradenitis...",
                "category": "company",
                "datetime": 1790982295,
                "headline": "Merck (MRK) Reports Positive Phase 2b Tulisokibart Results In Hidradenitis Suppurativa"
              },
              {
                "id": 142593872,
                "url": "https://finnhub.io/api/news?id=499bf9bb38b2e7b37ffd4baa210386aa2765fea7f5aabdb08f96d7dabdf7322d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Track weekly dividend updates for Dividend Champions, Contenders & Challengers—see dividend changes, upcoming ex-dividend and pay dates. Read it here.",
                "category": "company",
                "datetime": 1790965134,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week October 4"
              },
              {
                "id": 142591361,
                "url": "https://finnhub.io/api/news?id=95613688eae498627faf1e9092765e34d9fd7c907f05ffb6d9f5ff73e0147392",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Curious about the top performers within the dow jones index in the middle of the day on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.",
                "category": "company",
                "datetime": 1790959214,
                "headline": "What's going on in today's session: dow jones movers"
              },
              {
                "id": 142588420,
                "url": "https://finnhub.io/api/news?id=3e9acb61c8beb0770b8746219d57ea06bd2a725b259e6bcf4015e587d2ae1091",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Eli Lilly just posted a 47.7% revenue surge while rivals like Novo Nordisk are watching earnings fall, and a fresh pipeline catalyst could push Lilly toward a valuation Wall Street has only seen from two companies in history.",
                "category": "company",
                "datetime": 1790946032,
                "headline": "Prediction: Eli Lilly Could Be the Next $2 Trillion Drugmaker"
              },
              {
                "id": 142590478,
                "url": "https://finnhub.io/api/news?id=f3811fb0268670d0a3fadaa1f32444c29b09a67de3d3d33d9abb18b71da84971",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/02/Charts-Of-Financial-Instruments-With-Var.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Friday's regular session has eight sectors higher and three lower, with growth sectors holding two of the top three positions. The leaders are clustered, with less than a quarter-point separating the top three sectors.",
                "category": "company",
                "datetime": 1790938892,
                "headline": "8 Of 11 Sectors Rise Friday As Growth Leads"
              },
              {
                "id": 142585466,
                "url": "https://finnhub.io/api/news?id=67bda7f26ae04d0d3f35078b1e3e515457b65d707cb614ee0369159ab7b04c5e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Pfizer's revenue over the past twelve months was 0.2% lower than a year earlier. When sales are flat, look at what management leads with on earnings calls to see where it expects growth. Since early 2025, Pfizer's management has changed what it leads with. It used to lead with the work of absorbing a company it had bought. It now leads with drugs it has not launched. What was that deal.",
                "category": "company",
                "datetime": 1790936840,
                "headline": "How Has Pfizer's Story Changed?"
              },
              {
                "id": 142560878,
                "url": "https://finnhub.io/api/news?id=961fc0d729de799f5405d148bd029ba8661ce70aa4212036021b8d1e84e7bbdd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck's (MRK) data from a phase 2b study evaluating tulisokibart in hidradenitis suppurativa looks s",
                "category": "company",
                "datetime": 1790872695,
                "headline": "Merck's Tulisokibart Data From Hidradenitis Suppurativa Trial Looks Solid, UBS Securities Says"
              },
              {
                "id": 142560847,
                "url": "https://finnhub.io/api/news?id=1bf9d5370d40493d3cde7b4f3de6878d5df419162b60a63c2108f9c48be13b7f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Both JNJ and MRK have surged in 2026, but a looming patent cliff and a balance sheet loaded with acquisition debt mean one of these pharma dividends faces a reckoning that retirement investors cannot afford to ignore.",
                "category": "company",
                "datetime": 1790871325,
                "headline": "JNJ or MRK: One Dividend Is Built to Last, One Faces a Reckoning"
              },
              {
                "id": 142560840,
                "url": "https://finnhub.io/api/news?id=e1c08e4bbb8e459a2d7b192134c7bdddeb78f099fdf34d930fe361886eba3ba7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Eli Lilly (LLY) management said on its second-quarter 2026 call that the price of Zepbound, its obesity drug, will go down. The company's sales growth rests on two drugs whose prices are falling - Zepbound and Mounjaro. That makes it difficult to call the stock's coming twelve months. So how do you really understand the risk you are taking with Eli Lilly stock? Well, you can look at the options market.",
                "category": "company",
                "datetime": 1790869272,
                "headline": "What Is The Options Market Telling Us About Eli Lilly Stock?"
              },
              {
                "id": 142562919,
                "url": "https://finnhub.io/api/news?id=1fbd8e26de53dbf149d1347b293aa371833389e270ea042e9abe496c51f0a778",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The cancer pipeline gave Moderna's shares a rocket boost. Citi, however, just checked the stock’s price tag and wasn’t exactly impressed.",
                "category": "company",
                "datetime": 1790868417,
                "headline": "Why Citi Is Sounding the Alarm on Moderna Stock"
              },
              {
                "id": 142559760,
                "url": "https://finnhub.io/api/news?id=8f361b2eb02af46d7061280f4e60d7ffa0b2f309294d3963a2bdce903cc74845",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Citigroup just told investors to sell Moderna and the stock responded by climbing 3%, raising one pointed question about whether pipeline optimism has fully broken free from Wall Street's valuation warnings.",
                "category": "company",
                "datetime": 1790866811,
                "headline": "Moderna Climbs 3% Despite Citigroup’s Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water"
              },
              {
                "id": 142559758,
                "url": "https://finnhub.io/api/news?id=ba62494783baca55efca70dbdf52bd4ca927c3ef39de76c2152ec3cd0760a12d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "MRK's tulisokibart meets the phase IIb HS study's primary endpoint, with high and medium-dose regimens showing superiority over placebo at week 16.",
                "category": "company",
                "datetime": 1790859300,
                "headline": "Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study"
              },
              {
                "id": 142557769,
                "url": "https://finnhub.io/api/news?id=716457aa4c02c97192c6401e34f80d7738cf68c917c0e25ebdf4355934fe2220",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna stock rallied by triple digits when positive news rolled in for its cancer vaccine. But is mRNA ready to return to the limelight?",
                "category": "company",
                "datetime": 1790856059,
                "headline": "Is A Cancer Vaccine Coming? Moderna, Merck Boosted By The Buzz"
              },
              {
                "id": 142557734,
                "url": "https://finnhub.io/api/news?id=299273e9cf56ccf03c135ac8c65f16b744b9d9e4c0c821df08ace4cb4fb03f5a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "AbbVie's stock climbs 25.4% in six months as Skyrizi, Rinvoq and neuroscience drugs fuel growth, but Humira erosion and competitive pressures remain.",
                "category": "company",
                "datetime": 1790853060,
                "headline": "ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell?"
              },
              {
                "id": 142556642,
                "url": "https://finnhub.io/api/news?id=dd23418a023f2cf2edcabe9a767615e1a6f2e168396e5f995ffe41e06600babd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "RAHWAY, N.J., October 01, 2026--Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29",
                "category": "company",
                "datetime": 1790851500,
                "headline": "Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29"
              },
              {
                "id": 142524865,
                "url": "https://finnhub.io/api/news?id=222ba29da438d1aab5a1d74e6c762d213e441897ce1585bfec5432cd76c60767",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna’s rally has priced in unrealistic expectations for its cancer drug sales.",
                "category": "company",
                "datetime": 1790806620,
                "headline": "Citi delivers major verdict after Moderna’s remarkable 703% run"
              },
              {
                "id": 142524864,
                "url": "https://finnhub.io/api/news?id=dc3cb7978cf4c8aeeedece41f034fa185c9c0f2599398cece53a4585b9a15e4f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "In the latest trading session, Merck (MRK) closed at $145.31, marking a -2.66% move from the previous day.",
                "category": "company",
                "datetime": 1790801404,
                "headline": "Why Merck (MRK) Dipped More Than Broader Market Today"
              },
              {
                "id": 142524101,
                "url": "https://finnhub.io/api/news?id=c4a24a8a74cef8fdfe88fdb4b52791e7d289346eb6fb12519590d0f456753d02",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Citi downgrades Moderna to Sell from Hold, saying the data around its cancer vaccine, instimeran autogene, isn’t enough to justify the valuation.",
                "category": "company",
                "datetime": 1790799300,
                "headline": "Citi Downgrades Moderna Stock, Warning $80 Billion Valuation Asks Too Much of Cancer Pipeline"
              },
              {
                "id": 142524002,
                "url": "https://finnhub.io/api/news?id=ca3b626f6371b67d4ed3a6fb6d3bb6adcab9be810769197aff832a5dc7207b7f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Apple, Microsoft and Broadcom face contrasting growth drivers and risks, from AI and cloud demand to capacity constraints and customer concentration.",
                "category": "company",
                "datetime": 1790796000,
                "headline": "Top Analyst Reports for Apple, Microsoft & Broadcom"
              },
              {
                "id": 142522688,
                "url": "https://finnhub.io/api/news?id=0093b0cd464267ac6c1513a5f23552a3363364456c7f26595de3332df4bb8e51",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index one hour before the close of the markets on Wednesday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1790795413,
                "headline": "Stay informed with the top movers within the dow jones index on Wednesday."
              },
              {
                "id": 142522943,
                "url": "https://finnhub.io/api/news?id=c747aebba32eb636e3b57420d8499423e7bbb2b046a2042871b0d126d296b891",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Johnson & Johnson (JNJ) stock returned around 52% in the twelve months, against 17% for the S&P 500. A $10,000 holding became about $15,220. Over that period, J&J’s revenue growth accelerated even as the company navigated the anticipated loss of exclusivity and biosimilar erosion for STELARA. If that shift showed up in J&J's calls and filings first, a reader could have spotted it early. So was J&J's run in plain sight before it began.",
                "category": "company",
                "datetime": 1790794880,
                "headline": "Was The Run In JNJ Stock Hiding In Plain Sight?"
              },
              {
                "id": 142522976,
                "url": "https://finnhub.io/api/news?id=e49692902d1eb8f706a634d7d2987e55a7ba911992b4d00d89e8914a6a247d16",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck & Co Inc. (NYSE:MRK) on Wednesday presented initial results from its Phase 2b MK-7240-012 trial at the European Academy of Dermatology and Venereology (EADV) 2026 Congress. Phase 2b Trial Delivers Positive Results The study evaluated tulisokibart—an investigational monoclonal antibody targeting tumor necrosis factor-like cytokine 1A (TL1A)—in patients with moderate to severe hidradenitis suppurativa. The trial met its primary endpoint of Hidradenitis Suppurativa Clinical Response 50 (HiSCR",
                "category": "company",
                "datetime": 1790792953,
                "headline": "Merck Says Investigational Skin Therapy Shows Potential"
              },
              {
                "id": 142521986,
                "url": "https://finnhub.io/api/news?id=9cc9bac25ab6f4b0cc77442bcc076f9dfa4abbaf139a9918132c7658d38d8900",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna falls after Citi downgrades shares to Sell from Hold, saying its recent rally has gone too far.",
                "category": "company",
                "datetime": 1790789400,
                "headline": "Moderna, Cerebras, Jabil, HPE, Cal-Maine, Mattel, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 142521908,
                "url": "https://finnhub.io/api/news?id=f496bf2a81d5dc6623fc202d50eaf5f7406170ca337578f1f207acaa57167f5c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "There is probably no dividend cut on the horizon for these healthcare companies.",
                "category": "company",
                "datetime": 1790788801,
                "headline": "2 Outstanding Dividend Stocks to Buy and Hold for a Decade"
              },
              {
                "id": 142559721,
                "url": "https://finnhub.io/api/news?id=297d7b9403786f1da6e4a279a0d6546a8726b21dbc06e1562265d42c1bc0020f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "AbbVie, Johnson & Johnson and Merck offer growing dividends alongside healthcare pipeline catalysts, regulatory approvals and rising analyst price targets heading into 2027.",
                "category": "company",
                "datetime": 1790782500,
                "headline": "3 Healthcare Dividend Stocks Offering More Than Just Income"
              },
              {
                "id": 142520808,
                "url": "https://finnhub.io/api/news?id=72a16884875e8205de3652d0399aae55c3f3a4b916c99485ad73dc7a499774f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Pfizer's shares cost more than Johnson & Johnson's for each dollar of reported profit, even after factoring in a loss quarter over the past year. Investors usually pay more for growth, yet Pfizer (PFE) had the weakest sales growth of the six companies in its peer group. Are you overpaying for Pfizer stock versus its rivals.",
                "category": "company",
                "datetime": 1790782145,
                "headline": "Are You Overpaying For Pfizer Stock Versus Its Rivals?"
              },
              {
                "id": 142522031,
                "url": "https://finnhub.io/api/news?id=63454becd4abb8682a7c6937f2784e56df98e658bfd714754092494ebe7559ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna stock has rallied since the company unveiled clinical updates to its cancer vaccine in collaboration with Merck in late August.",
                "category": "company",
                "datetime": 1790782080,
                "headline": "Moderna and Fair Isaac: The Best and Worst S&P 500 Stocks for the Third Quarter"
              },
              {
                "id": 142522033,
                "url": "https://finnhub.io/api/news?id=0c7f11fc2e27afae3e335037102ba549b3d2f5e4fb450b1c5af9210de361c233",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "MRNA's respiratory vaccine expansion and promising oncology results offer potential growth as COVID-19 demand normalizes.",
                "category": "company",
                "datetime": 1790780460,
                "headline": "Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?"
              },
              {
                "id": 142520809,
                "url": "https://finnhub.io/api/news?id=76d46d09777c71c504574fbb4fc04c17977db7ccfaa9d0806d18f0f7f44a6972",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) stock returned 96% in the past twelve months, against 16.8% for the S&P 500. With the shares 4.0% below their 52-week high, you need a reason Merck can keep growing. In its fiscal Q2 2026 call, management looked past its best-selling drug to newer ones. So what is Merck stock's biggest opportunity from here.",
                "category": "company",
                "datetime": 1790779413,
                "headline": "What Is Merck Stock's Biggest Opportunity?"
              },
              {
                "id": 142520851,
                "url": "https://finnhub.io/api/news?id=2c75b84a8e3ed43d9ef0b377df0785ea40960d26eccc6c99c516b20b5a6e7982",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "After nearly quadrupling over the past month, it's time to get out of Moderna stock, a Citi analyst said Wednesday as he downgraded shares.",
                "category": "company",
                "datetime": 1790777121,
                "headline": "After Moderna's Dizzying Rally, It's Time To Sell, Says Analyst"
              },
              {
                "id": 142557492,
                "url": "https://finnhub.io/api/news?id=a38ca6bac6dfbfa01fd8d63f7e92381f6949b3d2aca9a04d8fc67da8d0602cf7",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/30/Augsburg--Bavaria--Germany---March-21--2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Moderna stock dips as Juan Andres returns as COO, Jerh Collins retires, and the company expands its vaccine and cancer therapy portfolio.",
                "category": "company",
                "datetime": 1790776712,
                "headline": "What's Going On With Moderna Stock on Wednesday?"
              },
              {
                "id": 142517577,
                "url": "https://finnhub.io/api/news?id=ce2eba22449a0950f1937137a8d491338f3c95da529f8f44a9d9078f6136566f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Citigroup just slapped a Sell rating on one of 2026's most explosive biotech stocks, warning that soaring investor hopes around a cancer vaccine partnership with Merck have carried the valuation into dangerous territory.",
                "category": "company",
                "datetime": 1790775737,
                "headline": "Moderna Sinks 6% on Citi Downgrade; Merck and Pfizer Stay Flat"
              },
              {
                "id": 142517579,
                "url": "https://finnhub.io/api/news?id=cad063a38776882f3d4bfcc7ab2dff97d876e551e89ca909590b24353d12b63a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.",
                "category": "company",
                "datetime": 1790774233,
                "headline": "3 Cash-Producing Stocks with Open Questions"
              },
              {
                "id": 142520852,
                "url": "https://finnhub.io/api/news?id=28e32e8ee7e005ddb76aeb14811a95e1ad01c6a5c256b8356069e328e95e0a6e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna falls after Citi downgrades shares to Sell from Hold, saying its recent rally has gone too far.",
                "category": "company",
                "datetime": 1790773380,
                "headline": "Moderna, Concentrix, Boeing, HPE, Robinhood, Cal-Maine, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 142516716,
                "url": "https://finnhub.io/api/news?id=fa47ec443f59963c3625e8ac707d08d8347ac5b0f28491dd28769751e1a9eb0b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Citi downgrades Moderna to Sell from Hold, saying the data around its cancer vaccine, instimeran autogene, isn’t enough to justify the valuation.",
                "category": "company",
                "datetime": 1790771280,
                "headline": "Moderna Stock Has Run Too Far, Too Fast. Why Citi Just Downgraded It to Sell."
              },
              {
                "id": 142514562,
                "url": "https://finnhub.io/api/news?id=37c3db441a5a3871966c1ef02f122b9a72f396ea78b66b16f2adc5e201ef7322",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "RAHWAY, N.J., September 30, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from MK-7240-012, a Phase 2b multicenter, randomized, double-blind, placebo-controlled trial evaluating tulisokibart, an investigational humanized monoclonal antibody targeting tumor necrosis factor-like cytokine 1A (TL1A), in patients with moderate to severe hidradenitis suppurativa (HS). These data will be presented in a Late-Breaking News",
                "category": "company",
                "datetime": 1790770500,
                "headline": "Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)"
              },
              {
                "id": 142513047,
                "url": "https://finnhub.io/api/news?id=ba80e6b6a456360c65d18842a093d154f3e547670481bb8a3e14a8d0b26cebd6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "SHCD is missing some of the healthiest dividend stocks.",
                "category": "company",
                "datetime": 1790765401,
                "headline": "SCHD's Top Sector Bet Is Healthcare at 20.7%. I'm Not Sure What's More Surprising: What It Doesn't Hold, or What It Does."
              },
              {
                "id": 142517116,
                "url": "https://finnhub.io/api/news?id=c7311054be2a4569fbfc48f3945c236f6a4bf1dd04aa3587eecc4e065efecdc4",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Results mark the first positive Phase 2 data for an anti-TL1A monoclonal antibody in dermatologyTulisokibart was designed to help address immuno-fibrosis, a key driver of disease progression in HSMerck (NYSE:MRK), known",
                "category": "company",
                "datetime": 1790756328,
                "headline": "Merck’s Tulisokibart Meets Phase 2b Primary Endpoint In Hidradenitis Suppurativa, Achieves HiSCR50 of 72% And 64% Vs 35% for Placebo At Week 16"
              },
              {
                "id": 142512422,
                "url": "https://finnhub.io/api/news?id=a07c7be544ea12f2e2cb5668125599ae22faaf8f3362dcc748e47fbe03d2ed86",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2187784921/image_2187784921.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Personalis shareholders remain exposed to downside in TEM shares while having limited ability to benefit from further TEM appreciation above $48.42. Learn more about PSNL stock here.",
                "category": "company",
                "datetime": 1790745328,
                "headline": "Personalis: The Wrong Side Of The Merger"
              },
              {
                "id": 142500404,
                "url": "https://finnhub.io/api/news?id=5c46b88563d4b18775c99a78b1430bf120d2ee6642d4c39ef932532e9472fccc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The agreement can reach $2.13 billion, although SPR2015 remains a preclinical cancer candidate.",
                "category": "company",
                "datetime": 1790709305,
                "headline": "Merck Stock Slips 1.5% as $400 Million Buys KRAS Rights"
              },
              {
                "id": 142500405,
                "url": "https://finnhub.io/api/news?id=ca945c3695f55fe330f6965ed8d8956a58f8b4ec01d26260fd243df2f2731010",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Looking back on branded pharmaceuticals stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Merck (NYSE:MRK) and its peers.",
                "category": "company",
                "datetime": 1790709122,
                "headline": "Unpacking Q2 Earnings: Merck (NYSE:MRK) In The Context Of Other Branded Pharmaceuticals Stocks"
              },
              {
                "id": 142499987,
                "url": "https://finnhub.io/api/news?id=d86a89f12f7a3769625ba57f71398b516023a72b2444d33a1d6a23ea31e36d7c",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.",
                "category": "company",
                "datetime": 1790709009,
                "headline": "Which dow jones stocks are moving on Tuesday?"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.6,
            "source_article_count": 243,
            "discarded_article_count": 223
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 20.1,
        "grade": "一般",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 1,
          "macdPoints": 3.2,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1,
            "vcp_reason": "跌縮量(近10日4日)；站上MA50；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 9492126.666666666,
              "down_days": 5,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 9131590,
              "avg_vol_20": 10196265,
              "avg_vol_30": 9492126.666666666,
              "range_pct_10": 0.0927714970880438,
              "range_pct_20": 0.10119910928400128,
              "range_pct_30": 0.10119910928400128,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.9620172929283849,
              "dist_to_20d_high": 0.04961912810971366,
              "down_shrink_days": 4,
              "breakout_level_20d": 153.57001,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.9167224666740243
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 2.4,
          "shortRsiPoints": 1,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.8,
            "details": {
              "atrPct": 2.6589242891401166,
              "turnoverUsdM": 1639.3833749999997,
              "liquidityPoints": 0.8,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.MRK",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 138.1886,
            "strength_details": {
              "ma_score": 2,
              "atr_score": 2,
              "rsi_score": 1,
              "macd_score": 2.5,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.2,
            "stop_loss_percent": 5.3,
            "take_profit_price": 155.4124,
            "target_multiplier": 1.9,
            "technical_strength": 1.93,
            "take_profit_percent": 6.5
          },
          "positionPoints": 1.8,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2222988120699874,
          "stopLossPercent": 5.317848578280233,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 78.57,
    "atr": {
      "atr": 3.8807,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.66
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "平衡",
      "score": 6,
      "value": 16.17
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.0768
    },
    "kdj": {
      "d": 50.72,
      "j": 62.44,
      "k": 54.63,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 49.64
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 7886100,
      "recentSlope": 607780,
      "previousSlope": -1794920
    },
    "rsi": 45.45,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 151.1145,
      "position": "SAR喺價上",
      "distancePct": 3.54,
      "previousTrend": "下降"
    },
    "ma50": 145.1234,
    "macd": {
      "macd": -0.10716233893776916,
      "trend": "看漲",
      "signal": -0.1271133155327968,
      "histogram": 0.019950976595027647
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 146.0199,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.22,
      "score": 6,
      "avgVolume": 9199905,
      "currentVolume": 11232500
    },
    "derived": {
      "ma20": 145.7415,
      "ma50": 145.1234,
      "prevClose": 145.19,
      "avgVolume10": 9289050,
      "avgVolume20": 9199905,
      "changePercent": 0.52,
      "avgVolumeForScore": 9199905
    },
    "ma_cross": {
      "ma20": 145.7415,
      "ma50": 145.1234,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "接近",
      "score": 6,
      "prevMa20": 145.7875,
      "prevMa50": 144.7718,
      "spreadPct": 0.43,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 139.776,
      "upper": 151.707,
      "position": "上半部"
    },
    "rsi_short": 61.77,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.22
    }
  }
}

{
  "close": 145.95,
  "volume": 11232500,
  "changePercent": 0.52
}